Zeo ScientifiX (ZEOX) 10-K 14 Feb 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Oct. 31, 2022	Feb. 13, 2023	Apr. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Oct. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--10-31
Entity File Number	000-55008
Entity Registrant Name	ORGANICELL REGENERATIVE MEDICINE, INC.
Entity Central Index Key	0001557376
Entity Tax Identification Number	47-4180540
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	3321 College Avenue
Entity Address, Address Line Two	Suite 246
Entity Address, City or Town	Davie
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33314
City Area Code	(888)
Local Phone Number	963-7881
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 11,960,956
Entity Common Stock, Shares Outstanding		1,463,957,717
Auditor Name	Marcum
Auditor Firm ID	688
Auditor Location	Fort Lauderdale, FL

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Oct. 31, 2022	Oct. 31, 2021
Current Assets
Cash	$ 3,753,097	$ 108,570
Accounts receivable, net of allowance for bad debts	55,110	104,150
Receivables from related party	128,939
Other receivables	7,433
Prepaid expenses	173,152	69,647
Inventories	248,510	234,827
Total Current Assets	4,366,241	517,194
Property and equipment, net	1,683,516	1,113,416
Other assets – right of use	110,995	254,665
Security deposits	39,936	47,682
TOTAL ASSETS	6,200,688	1,932,957
Current Liabilities
Accounts payable and accrued expenses	2,378,531	1,873,022
Accrued liabilities to management		1,542,130
Notes payable		4,392
Advances payable	220,897	220,897
Finance lease obligations	143,748	92,270
Operating lease obligations	82,407	114,231
Deferred revenue		9,575
Debentures payable		144,000
Promissory Note, net of debt discount	563,111
Commitment Fee Shortfall Obligation	174,462
Commitment to repurchase shares in connection with settlement of litigation	500,000
Liabilities attributable to discontinued operations		125,851
Total Current Liabilities	4,063,156	4,126,368
Long term finance lease obligations	220,340	331,748
Long term operating lease obligations	28,588	140,434
Total Liabilities	4,312,084	4,598,550
Stockholders’ Equity (Deficit)
Common stock, $0.001 par value, 2,500,000,000 shares authorized; 1,479,126,390 and 1,132,361,005 shares issued and outstanding, respectively	1,479,126	1,132,361
Additional paid-in capital	50,930,784	37,826,795
Accumulated deficit	(50,521,306)	(41,624,749)
Total Stockholders’ Equity (Deficit)	1,888,604	(2,665,593)
TOTAL LIABILITIES, SHARES SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ EQUITY (DEFICIT)	6,200,688	1,932,957
Series C Preferred Stock [Member]
Shares Subject To Possible Redemption
Preferred stock value

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Oct. 31, 2022	Oct. 31, 2021
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,500,000,000	2,500,000,000
Common stock, shares issued	1,479,126,390	1,132,361,005
Common stock, shares outstanding	1,479,126,390	1,132,361,005
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100	100
Preferred stock, shares issued	100	0
Preferred stock, shares outstanding	100	0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Income Statement [Abstract]
Revenues	$ 6,491,008	$ 5,597,487
Cost of revenues	753,534	547,881
Gross profit	5,737,474	5,049,606
General and administrative expenses	14,580,434	17,793,709
Loss from operations	(8,842,960)	(12,744,103)
Other income (expense)
Interest expense	(398,260)	(37,934)
Change in Commitment Fee Shortfall Obligation	(30,692)
Gain from write-off of liabilities attributable to discontinued operations	125,851
Other	249,504	25,477
Loss before taxes	(8,896,557)	(12,756,560)
Provision for income taxes
Net loss	$ (8,896,557)	$ (12,756,560)
Net loss per common share - basic and diluted	$ (0.01)	$ (0.01)
Weighted average number of common shares outstanding - basic and diluted	1,137,645,970	1,059,488,329

CONSOLIDATED CHANGES IN STOCKHO

CONSOLIDATED CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Oct. 31, 2020	$ 939,943	$ 26,536,430	$ (28,868,189)	$ (1,391,816)
Beginning balance, shares at Oct. 31, 2020	939,942,783
Sale of common stock	$ 52,766	2,654,504		2,707,270
Sale of common stock, Shares	52,766,234
Exchange of accounts payable for stock	$ 677	112,529		113,206
Exchange of accounts payable for stock, Shares	676,988
Stock issued for future services	$ 60	9,940		10,000
Stock issued for future services, shares	60,000
Stock-based compensation	$ 138,915	8,513,392		8,652,307
Stock based compensation, Shares	138,915,000
Net loss			(12,756,560)	(12,756,560)
Ending balance, value at Oct. 31, 2021	$ 1,132,361	37,826,795	(41,624,749)	(2,665,593)
Ending balance, shares at Oct. 31, 2021	1,132,361,005
Sale of common stock	$ 282,500	7,007,500		7,290,000
Sale of common stock, Shares	282,500,000
Exchange of accounts payable for stock	$ 5,000	112,500		117,500
Exchange of accounts payable for stock, Shares	5,000,000
Stock-based compensation	$ 52,650	3,863,940		3,916,590
Stock based compensation, Shares	52,650,000
Capital contributed by Executive		250,000		250,000
Warrants issued to executives as payment for outstanding compensation		649,740		649,740
Executive forgiveness of employment obligations in connection with Restructuring		1,526,893		1,526,893
Commitment to repurchase shares in connection with settlement of litigation		(500,000)		(500,000)
Common stock issued as commitment fee for Promissory Note	$ 4,615	151,616		156,231
Common stock issued as commitment fee for Promissory Note, Shares	4,615,385
Stock issued in settlement of litigation	$ 2,000	41,800		43,800
Stock issued in settlement of litigation, Shares	2,000,000
Net loss			(8,896,557)	(8,896,557)
Ending balance, value at Oct. 31, 2022	$ 1,479,126	$ 50,930,784	$ (50,521,306)	$ 1,888,604
Ending balance, shares at Oct. 31, 2022	1,479,126,390

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (8,896,557)	$ (12,756,560)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	332,508	52,702
Amortization of OID and commitment fee discount – Promissory Note	323,111
Change in Commitment Fee Shortfall Obligation	30,692
Gain from write-off of liabilities attributable to discontinued operations	(125,851)
Gain from write-offs and settlements of accounts payable and notes payable	(249,504)
Reserve for bad debt	27,500
Write-off of inventory	37,455
Stock issued in settlement of litigation	43,800
Stock-based compensation	3,916,590	8,652,307
Changes in operating assets and liabilities:
Accounts receivable, net of allowance for bad debts	17,148	(74,765)
Receivables from related party	(128,939)
Other receivable	(7,433)
Prepaid expenses	(103,505)	19,143
Inventories	(51,138)	(88,016)
Accounts payable and accrued expenses	1,035,609	1,149,307
Accrued liabilities to management	657,003	385,835
Security deposits	(14,754)	(29,882)
Deferred revenue	(9,575)	9,575
Net cash used in operating activities	(3,165,840)	(2,680,354)
CASH FLOWS FROM INVESTING
Purchase of fixed assets	(824,743)	(424,742)
Net cash used in investing activities	(824,743)	(424,742)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of notes payable	540,000
Capital contributed by executive	250,000
Payments on finance lease	(59,930)	(50,844)
Repayments of notes payable	(364,960)	(33,557)
Proceeds from sale of common stock	7,270,000	2,707,270
Net cash provided by financing activities	7,635,110	2,622,869
Increase (decrease) in cash	3,644,527	(482,227)
Cash at beginning of period	108,570	590,797
Cash at end of period	3,753,097	108,570
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for taxes
Cash paid for interest	78,625	28,473
NON-CASH INVESTING AND FINANCING TRANSACTIONS:
Executive forgiveness of employment obligations in connection with Restructuring	1,526,893
Warrants issued to executives as payment for outstanding compensation	649,740
Stock issued in exchange for accounts payable	117,500
OID discount on proceeds received from Promissory Note	60,000
Stock purchased from payments due on accounts payable	20,000
Common stock issued as commitment fee for Promissory Note	156,231
Commitment Fee Shortfall Obligation	143,769
Commitment to repurchase shares in connection with settlement of litigation	500,000
Promissory note issued for past due Professional Fees	256,000
Purchase of fixed assets included in accounts payable	77,865	71,269
Exchange of accounts payable for common stock		113,206
Stock issued for future services		10,000
Finance lease obligations		304,873
Operating lease – right of use assets		$ 235,313

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	12 Months Ended
	Oct. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Organicell Regenerative Medicine, Inc. f/k/a Biotech Products Services and Research, Inc. (“Organicell” or the “Company”) was incorporated on August 9, 2011 in the State of Nevada. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Our proprietary products are principally used in the health care industry administered through doctors and clinics (collectively, “Providers”). On May 21, 2018, the Company filed a Certificate of Amendment with the Secretary of State of Nevada to change the Company’s name from Biotech Products Services and Research, Inc. to Organicell Regenerative Medicine, Inc., effective June 20, 2018 (the “Name Change”) and during November 2021 the Name Change was effectuated in the marketplace by the Financial Industry Regulatory Agency. For the years ended October 31, 2022 and 2021, the Company principally operated through General Surgical of Florida, Inc., a Florida corporation and wholly owned subsidiary, which was formed to sell the Company’s therapeutic products to Providers. The Company’s leading product, Zofin™ (also known as Organicell TM In June 2021, the Company announced that it was launching a service platform for its first autologous product called Patient Pure X TM TM TM TM In November 2020, the Company formed Livin’ Again Inc., a wholly owned subsidiary, for the purpose of among other things, providing independent education, advertising and marketing services, to Providers that provide medical and other healthcare, anti-aging and regenerative services. Due to limited activity, as of October 31, 2022, the Company has abandoned any future plans to operate these services.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Oct. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Reclassifications Certain comparative figures have been reclassified to conform to the current year financial statement presentation. These reclassifications had no effect on the reported results of operations. An adjustment has been made to the Consolidated Statements of Cash Flows for the year ended October 31, 2021 to reclassify certain payments for the purchase of fixed assets. Concentrations of Risk Credit Risk The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $ 250,000 3,731,290 Major Customer During the fiscal year ended October 31, 2022, the Company sold a total of approximately $ 2,124,000 32.7 1,413,700 21.8 702,100 10.8 During the fiscal year ended October 31, 2021, the Company sold a total of approximately $ 2,140,000 37.6 709,000 12.5 881,600 15.7 The Company’s sales agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products. Major Supplier During the fiscal year ended October 31, 2022, the Company purchased the tissue raw material used in manufacturing of its products from two suppliers, of which each accounted for approximately $ 145,000 130,000 53.0 47.0 During the fiscal year ended October 31, 2021, the Company purchased the tissue raw material used in manufacturing of its products from two suppliers, of which each accounted for approximately $ 148,600 131,600 53.0 47.0 The Company’s supply agreements are non-exclusive and the Company does not believe it has any exposure based on the availability of raw materials and/or products from other suppliers. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates. Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Accounts Receivable Accounts receivable are recorded at net realizable value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to pay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. For the year ended October 31, 2022 and 2021, the Company recorded bad debt expense of $ 27,500 0 Inventory Inventory is stated at the lower of cost or net realizable value using the average cost method. The Company provides a reserve for potential excess, dated or obsolete inventories based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life. At October 31, 2022, the Company wrote off $ 37,455 Property and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of property and equipment range from 3 15 Leasehold Improvements Leasehold improvements in excess of $1,000 that are made in connection with leases having a term of more than 12 months are capitalized by the Company and amortized over the shorter of the useful life of the asset or the remaining lease periods and renewals that are deemed to be reasonably certain at the date the leasehold improvements are purchased. Costs associated with leasehold improvements that do not exceed $1,000 are expensed as incurred. Revenue Recognition The Company follows the guidance of FASB Accounting Standards Update (“ASU”) Topic 606 “Revenue from Contracts with Customers” which requires the Company to recognize revenue in amounts that reflect the prorata completion of the performance obligations of the Company required under the contracts. The Company recognizes revenue only when it transfers control of a promised good or service to a customer in an amount that reflects the consideration it expects to receive in exchange for the good or service. Our performance obligations are satisfied and control is transferred at a point-in-time, which is typically when the transfer and title to the product sold has taken place and there is evidence of our customer’s satisfactory acceptance of the product shipment or delivery except in those instances when the customer has made prior arrangements with the Company to store the product purchased by the customer at the Company’s facilities that is to be delivered at a later date to be designated by the customer. Net Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of fully vested common shares outstanding during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of fully vested shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity instruments. At October 31, 2022, the Company had 388,048,326 9,500,000 35,684,900 Stock-Based Compensation All stock-based payments are recognized in the financial statements based on their fair values. Research and Development Costs Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Our research and development expenses were $ 791,326 1,120,067 Income Taxes The Company files a consolidated tax return that includes all of its subsidiaries. Provisions for income taxes are based on taxes payable or refundable for the current year taxable income for federal and state income tax reporting purposes and deferred income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of the operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with FASB Topic 740 – Income Taxes. This pronouncement prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. The interpretation also provides guidance on recognition, derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. For the years ended October 31, 2022 and 2021 the Company incurred operating losses, and therefore, there was not any income tax expense amount recorded during those periods. There is a full valuation allowance established for the tax benefit associated with the net losses for the years ended October 31, 2022 and 2021. Valuation of Derivatives The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date. Sequencing The Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares. The Company currently has 2,500,000,000 1,463,957,717 Fair Value of Financial Instruments The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made. The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments. The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Level one Level two Level three The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company did not have any convertible instruments outstanding at October 31, 2022 and October 31, 2021 that contain derivatives. Operating Lease Obligations Under the provisions of Accounting Standards Update (ASU) No. 2016-02 (Topic 842) (“ASC 842”), the Company recognizes a right of use (“ROU”) asset and corresponding lease liability for all operating leases upon commencement of the lease. The Company applies the modified retrospective approach which includes a number of optional practical expedients on leases that commenced before the effective date of ASC 842, including continuing to account for leases that commenced before the effective date in accordance with previous guidance, unless the lease is modified and the inclusion of amounts pertaining to the maintenance portion of the leased assets. The Company’s policy is to treat operating leases that have a term of one year or less at lease commencement date and do not include a purchase option that is reasonably certain of exercise, consistent with the lease recognition approach as previously outlined under ASC 840. In addition, month to month leases which do not involve additional financial commitments on the part of the Company are also treated consistent with the lease recognition approach as previously outlined under ASC 840. The Company has established a capitalization threshold of $ 15,000 Subsequent Events The Company has evaluated subsequent events that occurred after October 31, 2022 through the financial statement issuance date for subsequent event disclosure or recording.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Oct. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has had limited revenues since its inception. The Company incurred net losses of $ 8,896,557 50,521,306 303,085 New United States Food and Drug Administration (“FDA”) regulations which were announced in November 2017 and which became effective beginning in May 2021 (postponed from November 2020 due to the COVID-19 pandemic) require that the sale of products that fall under Section 351 of the Public Health Services Act pertaining to marketing traditional biologics and human cells, tissues and cellular and tissue based products (“HCT/Ps”) can only be sold pursuant to an approved biologics license application (“BLA”). The Company has not obtained any opinion or ruling regarding the Company’s operations and whether the processing, sales and distribution of the products it currently produces would be subject to the FDA’s previously announced intended enforcement policies regarding HCT/P’s. In addition to the above, the adverse public health developments associated with the ongoing COVID-19 pandemic combined with the downturn in the overall United States and global economies have adversely affected the demand for our products and services by our customers and from patients of our customers and which currently still continue to have a negative impact to our business and the economy. As a result of the above, the Company’s efforts to establish a stabilized source of sufficient revenues to cover operating costs has yet to be achieved and ultimately may prove to be unsuccessful unless (a) the Company’s ability to process, sell and distribute the products currently being produced or developed in the future are not restricted; (b) the United States economy returns to pre-COVID-19 conditions; and/or (c) additional sources of working capital through operations or debt and/or equity financings are realized. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses and research and development costs related to development of new products and to perform required clinical studies in connection with the sale of its products. The Company does not have any assets to pledge for the purpose of borrowing additional capital. In addition, the Company relies on its ability to produce and sell products it manufactures that are subject to changing technology and regulations that it currently sells and distributes to its customers. The Company’s current market capitalization, common stock liquidity and available authorized shares may hinder its ability to raise equity proceeds. The Company anticipates that future sources of funding, if any, will therefore be costly and dilutive, if available at all. In view of the matters described in the preceding paragraphs, recoverability of the recorded asset amounts shown in the accompanying consolidated balance sheet assumes that (a) the Company is able to continue to produce products or obtain products under supply arrangements which are in compliance with current and future regulatory guidelines; (b) the United States economy returns to pre-COVID-19 market conditions; (c) the Company will be able to establish a stabilized source of revenues, including efforts to expand sales internationally and the development of new product offerings and/or designations of products; (d) obligations to the Company’s creditors are not accelerated; (e) the Company’s operating expenses remain at current levels and/or the Company is successful in restructuring and/or deferring ongoing obligations; (f) the Company is able to continue its research and development activities, particularly in regards to remaining compliant with the FDA and ongoing safety and efficacy of its products; and/or (g) the Company obtains additional working capital to meet its contractual commitments and maintain the current level of Company operations through debt or equity sources. There is no assurance that the products we currently produce will not be subject to the FDA’s previously announced intended enforcement policies regarding HCT/P’s and/or the Company will be able to complete its revenue growth strategy. There is no assurance that the Company’s research and development activities will be successful or that the Company will be able to timely fund the required costs of those activities. Without sufficient cash reserves, the Company’s ability to pursue growth objectives will be adversely impacted. Furthermore, despite significant effort since July 2015, the Company has thus far been unsuccessful in achieving a stabilized source of revenues. If revenues do not increase and stabilize, if the Company’s ability to process, sell and/or distribute the products currently being produced or developed in the future are restricted, and/or if additional funds cannot otherwise be raised, the Company might be required to seek other alternatives which could include the sale of assets, closure of operations and/or protection under the U.S. bankruptcy laws. As of October 31, 2022, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements.

RESTRUCTURING

RESTRUCTURING	12 Months Ended
	Oct. 31, 2022
Restructuring and Related Activities [Abstract]
RESTRUCTURING	NOTE 4 – RESTRUCTURING Effective July 13, 2022, the Company entered into (a) a binding letter of intent with Skycrest Holdings, LLC (“Skycrest”) and Greyt Ventures LLC (“Greyt,” and together with Skycrest, the “Skycrest/Greyt Group”) to invest $ 2,000,000 100,000,000 0.02 2,000,000 100,000,000 0.02 Pursuant to the binding letters of intent (the “LOIs”), the Company agreed to (a) make certain corporate governance changes as more fully described therein, including allowing the Investors to appoint new independent directors who will comprise a majority of the members of the Board; (b) enter into 36-month consulting agreements with each of Skycrest and Greyt (each, a “Consulting Agreement,” and collectively, the “Consulting Agreements”), pursuant to which (i) Skycrest and Greyt will provide certain advisory services to the Company as more fully set forth in the LOIs; and (ii) Skycrest and Greyt shall each be compensated for their services by the Company issuing to each of them ten year-warrants to purchase 150,000,000 0.02 Contemporaneously with entering into the respective LOIs, the Skycrest/Greyt Group and Beyond 100 each advanced Organicell $400,000 and $300,000, respectively (a total of $700,000) as good faith deposits against the $2,000,000 (a total of $4,000,000) purchase price for the Shares. On August 19, 2022 (“Closing”), the Company entered into stock purchase agreements (each, an “SPA” and collectively, the “SPAs”) with Skycrest Holdings, LLC (“Skycrest”), Greyt Ventures LLC (“Greyt”), Beyond 100 FZE (“Beyond 100”) and Smart Co. Holding Pte. Ltd. (“Smart Co,” and together with Skycrest, Greyt and Beyond 100, individually, an “Investor” and collectively, the “Investors”). Pursuant to the SPAs, the Company issued each Investor 50,000,000 shares of the Company’s common stock (“Shares”) at a price of $0.02 per Share ($1,000,000). In addition, under the SPAs with Skycrest and Greyt, the Company issued each of them 50 shares of newly designated Series C Non-Convertible Preferred Stock (the “Series C Preferred Shares”). The Series C Preferred Shares vote together with Shares of our common stock as a single class on all matters presented to a vote of stockholders, except as required by law and entitle Skycrest and Greyt to each exercise 25.5% of the total voting power of the Company. The SPAs with Skycrest and Greyt, also grant them the right, acting jointly, to designate a majority of the nominees to be elected to the Company’s board of directors at each annual meeting of the Company’s stockholders (the “Designation Right”). The Designation Right expires at such time as the Series C Preferred Shares are no longer outstanding. As a result of the issuance to Skycrest and Grey of the Series C Preferred Stock and the granting to them of the Designation Right, a “Change in Control” of the Company is deemed to have occurred. The SPA with Beyond 100 grants that Investor a right of first refusal for a period of 18 months from Closing with respect to any bona fide offer, or proposal received by the Company from or agreement in principal reached by the Company with a third party to enter into an exclusive arrangement providing for manufacturing, distributing, licensing, and commercializing any of its existing and/or future products and services to be manufactured, licensed and/or distributed by the Company or any of its subsidiaries in India. The SPAs also accord the Investors registration rights under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to which the Company has agreed to file a registration statement under the Securities Act with the Securities and Exchange Commission (the “SEC”) within 180 days of Closing and use its commercially reasonable efforts to cause such registration statement to be declared effective by the SEC within 60 days thereafter. The registration statement will cover the resale of the Shares pursuant to the SPAs, and in the case of Skycrest and Greyt, the Shares issued or issuable upon exercise of the Consulting Warrants. The SPAs also provide the Investors “piggy-back” registration rights with respect to their respective Shares. Consulting Agreements At Closing, the Company also entered into 36-month consulting agreements with each of Skycrest and Greyt (each, a “Consulting Agreement,” and collectively, the “Consulting Agreements”), pursuant to which (a) Skycrest and Greyt will provide certain advisory services to the Company as more fully set forth therein; and (b) Skycrest and Greyt are being compensated for their services by the Company issuing to each of them at closing ten (10) year-warrants to purchase 150,000,000 Shares at an exercise price of $0.02 per Share (the “Consulting Agreement Warrants”), which Warrants are exercisable on a “cashless” basis (see Note 13).

INVENTORIES

INVENTORIES	12 Months Ended
	Oct. 31, 2022
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 5 – INVENTORIES Schedule of inventories October 31, October 31, Raw materials and supplies $ 85,096 $ 92,601 Finished goods 163,414 142,226 Total inventories $ 248,510 $ 234,827

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Oct. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 6 – PROPERTY AND EQUIPMENT Schedule of property and equipment October 31, October 31, Computer equipment $ 26,881 $ 10,684 Finance lease equipment 544,378 544,378 Manufacturing equipment 625,979 258,791 Leasehold improvements 925,932 - 2,123,170 813,853 Less: accumulated depreciation and amortization (439,654 ) (107,146 ) 1,683,516 706,707 Construction in progress - 406,709 Total property and equipment, net $ 1,683,516 $ 1,113,416 Depreciation expense totaled $ 82,036 52,702 As described in Note 7, during the year ended October 31, 2021, the Company began the build-out of additional laboratory processing, product distribution and administrative office capacity at its Basalt Lab Lease location. The Basalt Lab Lease location became operational during May 2022 and amortization of these costs began during May 2022. Amortization expense totaled $ 250,472

LEASE OBLIGATIONS

LEASE OBLIGATIONS	12 Months Ended
	Oct. 31, 2022
Lease Obligations
LEASE OBLIGATIONS	NOTE 7 – LEASE OBLIGATIONS Finance Lease Obligations: During March 2019, the Company entered into a lease agreement for certain lab equipment in the amount of $ 239,595 4,513 1.00 4.5 15 During October 2021, the Company entered into a second lease agreement in the amount of $ 304,873 5,478 1.00 3.0 15 The weighted average remaining term of the Company’s Finance Leases as of October 31, 2022 was 35.8 months. The minimum lease payments pursuant to the Finance Leases are as follows: Schedule of minimum lease payment to finance lease Minimum Year Ended October 31, Rent 2023 $ 139,868 2024 83,783 2025 65,731 2026 65,731 2027 32,864 Thereafter - Total undiscounted finance lease payments 387,977 Less: imputed interest (23,889 ) Present value of finance lease liabilities $ 364,088 Operating Lease Obligations: Administrative Office The Company’s corporate administrative offices are leased from MariLuna, LLC, a Florida limited liability company which is owned by Dr. Mitrani. During July 2020, the Company entered into an extension of the operating lease agreement. The lease term is for an additional 36 months beginning July 1, 2020 and expiring June 30, 2023, with a monthly rental rate of $ 3,500 117,659 4.5 Beginning October 1, 2020, the Company entered into a second lease agreement with Mariluna LLC for office space located in Aspen, CO. The initial term of the lease was for one year, expiring on September 30, 2021 and the lease has been subsequently extended on a month to month basis. Under the terms of the lease, the Company is required to make monthly rental payments of $ 6,500 11,000 In connection with the Closing, both of the lease agreements with Mariluna LLC were terminated as of July 31, 2022 and the remaining ROU asset was written off and the security deposit was forfeited (see Note 13). Lease amortization expense for the year ended October 31, 2022 and 2021 was $ 29,670 38,037 On August 30, 2022, the Company entered into a one-year lease agreement (“LA Office Lease”) for office space in Los Angeles, California commencing September 1, 2022 and ending August 31, 2023. The Company was required to make a one-time prepayment of the annual rent in the amount of $ 160,000 10,000 Laboratory Facilities: In connection with the Company’s decision to again operate a placental tissue bank processing laboratory in Miami, Florida, during February 2019, the Company entered into a renewable month to month lease agreement (“Miami Lab Lease”) for an approximately 450 square foot laboratory and a 100 square foot administrative office space. In connection with the Miami Lab Lease, the Company was required to post a security deposit of $ 6,332 8,000 9,500 Effective October 10, 2022, the Company relocated its Miami laboratory to a 1,156 square foot administrative and laboratory facility at the Nova Southeastern University Center for Collaborative Research in Davie, Florida. This space is occupied pursuant to one year license agreement (“University Lease”) for an annual base license fee of $ 20,230 During March 2021, the Company entered into a lease agreement for an approximately 2,452 square foot commercial space located in Basalt, Colorado (the “Basalt Lab Lease”). The Company intends to build additional laboratory processing, product distribution and administrative office capacity from this location. The term of the Basalt Lab Lease is for three years and may be renewed for an additional (3) three-year term provided the Company is not in default (“First Renewal Option”). Rental expense is $ 6,800 13,600 925,932 In connection with the execution of the Basalt Lab Lease, the Company recorded a ROU asset and corresponding operating lease obligation of $ 235,313 4.5 Lease amortization expense for the years ended October 31, 2022 and 2021 was $ 76,351 47,967 The weighted average remaining term of the Company’s operating leases as of October 31, 2022 was 11.9 months. The minimum lease payments pursuant to the Basalt Lab Lease, the University Lease, and the LA Office Lease are as follows: Schedule of minimum lease payment to finance lease Minimum Year Ended October 31, Rent 2023 $ 237,606 2024 28,857 Thereafter - Total undiscounted operating lease payments 266,463 Less: imputed interest (3,590 ) Present value of operating lease liabilities $ 262,873

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Oct. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 8 – RELATED PARTY TRANSACTIONS On October 29, 2021, the Company entered into an Exchange Agreement (see Note 12) with the current executive officers of the Company (as well as other non-related party shareholders) whereby the executive officers of the Company exchanged an aggregate of 50,000,000 The Company’s corporate administrative offices were previously leased from MariLuna, LLC, a Florida limited liability company which is owned by Dr. Mitrani under a lease agreement that expires June 30, 2023. The Company paid a security deposit of $ 5,000 3,500 31,500 42,000 Beginning October 1, 2020, the Company entered into a second lease agreement with Mariluna LLC for office space located in Aspen, CO. The initial term of the lease was for one year, expiring on September 30, 2021 and the lease was subsequently extended on a month to month basis. Under the terms of the lease, the Company was required to make monthly rental payments of $ 6,500 11,000 58,500 78,000 In connection with Mr. Bothwell’s executive employment agreements, the Company agreed to reimburse Rover Advanced Technologies, LLC (“Rover”), a company owned and controlled by Mr. Bothwell for office rent and other direct expenses (phone, internet, copier and direct administrative fees, etc.) totaling $ 36,352 31,192 For the year ended October 31, 2022, the Company sold a total of approximately $ 702,100 20,820 101,715 For the year ended October 31, 2021, the Company sold a total of approximately $ 881,600 13,820 32,655 On February 26, 2020, the Company agreed to enter into a consulting agreement with the CMO to provide ongoing services to the Company. The CMO was entitled to receive compensation of $ 82,250 82,250 500,000 Effective December 21, 2020, the Company granted a bonus of $ 50,000 15,000,000 1,000,000 From time to time, Mr. Bothwell and/or his respective affiliates have advanced funds to the Company to pay for certain expenses of the Company. As of October 31, 2022 and 2021, $ 0 6,253 At October 31, 2021, salary amounts owed to Albert Mitrani, Dr. Mari Mitrani and Ian Bothwell were $ 275,924 362,455 843,478 430,200 563,455 Ian Bothwell waived all unpaid and accrued compensation in the amount of $1,043,478, in exchange for ten-year warrants to purchase 30,000,000 Shares at an exercise price of $0.02 per share, exercisable on a “cashless basis” and a cash payment of $50,000 at Closing. At Closing, Dr. George Shapiro terminated his consulting arrangement with the Company and waived all unpaid consulting fee obligations in the amount of $139,500 in exchange for ten-year warrants to purchase 3,150,000 Shares at an exercise price of $0.02 per share, exercisable on a “cashless basis.” During June 2022, Albert Mitrani made a capital contribution of $ 250,000

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Oct. 31, 2022
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 9 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Schedule of account payable and accrued expenses October 31, October 31, Accrued payroll related liabilities $ 666,780 $ 504,979 Lab equipment and supplies payables 477,255 117,606 Clinical trial payables 312,711 26,325 Legal fees payables 328,121 214,725 Other professional fees payables 90,993 259,442 Accrued IRS penalty 83,684 83,684 Accrued commissions payable 39,675 119,439 Construction payables 5,474 238,347 Other payables and accrued expenses 373,838 308,475 Accounts Payable and Accrued Expenses $ 2,378,531 $ 1,873,022

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Oct. 31, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 10 – NOTES PAYABLE Notes Payable Debentures On June 20, 2018, the Company issued a total of $ 150,000 6 th th On August 20, 2022, the Lender and the Company entered into a settlement and general release agreement whereby the Company agreed to make a lump sum payment of $ 87,500 35,041 Unsecured Promissory Note For Professional Fees Owed On January 24, 2022, the Company reached an agreement with a professional firm in connection with unpaid legal services owing as of December 31, 2021 in the amount of $ 278,340 256,000 166,000 7,500 22,340 Unsecured Promissory Note On February 5, 2019, the Company entered into an unsecured loan agreement with a third party with a principal balance of $ 25,000 March 8, 2019 0 4,392 Promissory Note – SPA On January 11, 2022, the Company entered into a Securities Purchase Agreement (“SPA”) with AJB Capital Investments, LLC (“Purchaser”) pursuant to which we sold a promissory note in the principal amount of $ 600,000 60,000 12,500 9,000 518,500 The Promissory Note matured on July 11, 2022, subject to extension at the option of the Company for up to an additional six month period (“Extension”), bears interest at a rate of 10 Under the terms of the Promissory Note, only following an event of default (as defined in the Promissory Note), is convertible into shares of the Company’s common stock at a conversion price equal to the lower of the “VWAP” (as hereinafter defined) of the common stock during (i) the twenty (20) trading day period preceding the issuance date of the Note; or (ii) the twenty (20) trading day period preceding the date of conversion of the Promissory Note. As used in the Promissory Note, “VWAP” means, for any date, the price of our common stock as determined by the first of the following clauses that applies: (i) if the common stock is then listed or quoted on one or more established stock exchanges or national market systems, the daily volume weighted average price of the common stock for such date on the trading market on which the common stock is then listed or quoted as reported by Bloomberg L.P.; or (ii) if the common stock is regularly quoted on an automated quotation system (including applicable tiers of the over-the-counter market maintained by OTC Market Group, Inc.) or by a recognized securities dealer, the volume weighted average price of the common stock for such date on the applicable OTC Markets Group, Inc. tier or as quoted by such securities dealer. In accordance with the terms of the SPA, as of October 31, 2022, the Company has reserved 36,923,080 The Promissory Note may be prepaid by the Company at any time without penalty. The Promissory Note also contains covenants, events of defaults, penalties, default interest and other terms and conditions customary in transactions of this nature. Pursuant to the terms of the SPA, the Company paid a commitment fee to the Purchaser in the amount of $ 123,000 3,076,923 0.04 33,231 1,538,462 0.0216 In the event that by the first anniversary of repayment of the Promissory Note by the Company, the Purchaser has not generated the amount of $ 300,000 The offer and sale of the Promissory Note to the Purchaser was made in a private transaction exempt from the registration requirements of the Securities Act of 1933, as amended (“Securities Act”), in reliance on exemptions afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. Upon the closing, the Company recorded a discount of the Promissory Note in the amount of $ 260,000 60,000 123,000 77,000 100,000 33,231 66,769 For the year ended October 31, 2022, $ 323,111 At October 31, 2022, the fair value of the Commitment Fee Shares was approximately $ 125,538 30,692 174,462 On January 12, 2023, the Promissory Note was paid in full. Credit Facility On September 19, 2019, the Company’s wholly owned subsidiary, General Surgical Florida, received $ 100,000 45.67

INCOME TAXES

INCOME TAXES	12 Months Ended
	Oct. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 11 – INCOME TAXES The Company files a consolidated federal income tax return that includes all of its subsidiaries. For the years ended October 31, 2022 and 2021, the Company incurred operating losses, and therefore, there was not any current income tax expense amount recorded during those periods. The consolidated provision for income taxes for October 31, 2022 and 2021 consists of the following: Schedule of provision for income tax Year Ended Year Ended 2022 2021 Current: Federal $ - $ - State - - Current Income Tax Expense (Benefit) $ - $ - Deferred: Federal $ 4,405,121 $ (2,651,809 ) State 1,079,723 (563,409 ) Deferred Income Tax Expense (Benefit) 5,484,844 (3,215,218 ) Change in Valuation Allowance (5,484,844 ) 3,215,218 Income tax provision $ - $ - Effective tax rates differ from the federal statutory rate of 21 Schedule of effective income tax rate October 31, October 31, Tax at federal statutory rate $ (1,868,277 ) $ (2,678,878 ) State taxes, net of federal benefit (386,555 ) (554,273 ) Permanent differences 400,100 27,070 Stock-based compensation 6,609,802 - Executive Forgiveness of employment obligations In connection with Restructuring 480,109 - Other 249,665 (9,137 ) Total income tax expense (benefit) 5,484,844 (3,215,218 ) Change in valuation allowance (5,484,844 ) 3,215,218 Income tax provision $ - $ - The Company had a federal net operating loss carryover of $ 14,297,151 9,126,151 6,554,845 The tax effects of temporary differences and carry-forwards that give rise to deferred tax assets and liabilities for the Company were as follows: Schedule of deferred tax assets and liabilities October 31, October 31, Deferred Tax Assets: Stock based compensation $ 798,239 $ 7,281,332 Accrued compensation - 480,109 Net operating loss carryforward-Federal 3,002,402 1,512,039 Net operating loss carryforward-State 396,530 282,780 Other 1,477 177 Total deferred tax assets: 4,198,648 9,556,437 Deferred Tax Liabilities: Property and equipment 302,447 175,392 Total deferred tax liabilities: 302,447 175,392 Valuation Allowance (3,896,201 ) (9,381,045 ) Net deferred tax assets $ - $ - FASB ASC 740 requires a valuation allowance against deferred tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. At October 31, 2022 and October 31, 2021, the net deferred tax asset was offset by a full valuation allowance. Pursuant to Code Sec. 382 of the Internal Revenue Code (“the Code”), the utilization of net operating loss carryforwards may be limited as a result of a cumulative change in stock ownership of more than 50% over a three-year period. The Company may be subject to such limitation. IRS Penalties The Company’s income tax returns for the periods since inception through the tax year ended October 31, 2015 were not filed with the Internal Revenue Service (“IRS”) until August 2017 (“Delinquent Filed Returns”). The Company’s income tax returns for the tax year ended October 31, 2016 were filed with the IRS during December 2017. In connection with the Delinquent Filed Returns, during the period September 2017 through October 2017, the Company received notices that it was being assessed approximately $ 90,000 20,000 83,684 83,684

CAPITAL STOCK

CAPITAL STOCK	12 Months Ended
	Oct. 31, 2022
Equity [Abstract]
CAPITAL STOCK	NOTE 12 – CAPITAL STOCK Preferred Stock The Company is authorized to issue 10,000,000 0.001 On August 17, 2022, the Company filed a Certificate of Designation for a newly created Series C Non-Convertible Preferred Stock consisting of 100 0.001 The Series C Preferred Shares vote together with shares of our common stock as a single class on all matters presented to a vote of stockholders, except as required by law. The Series C Preferred Shares are not convertible into common stock, do not have any dividend rights and do have a nominal liquidation preference. The Series C Preferred Shares also have certain protective provisions, such as requiring the vote of a majority of Series C Preferred Shares to change or amend their rights, powers, privileges, limitations and restrictions. Issued Shares In connection with the Closing (see Note 4), on August 19, 2022, the Company issued each of Skycrest and Greyt, 50 shares of the Series C Preferred Shares. The Series C Preferred Shares are automatically redeemed by the Company for nominal consideration at such time as the holder owns less than 50% of the Shares purchased pursuant to its SPA and Shares issued or issuable upon exercise of the Consulting Warrants or in the event the holder transfers or seeks to transfer the Series C Preferred Shares, other than by the laws of descent and distribution. Common Stock On December 21, 2020 and January 4, 2021, pursuant to the Nevada Revised Statutes and the Bylaws of the Company, the Board of Directors of the Company and the stockholders having the voting equivalency of 53.55% 1,500,000,000 2,500,000,000 Issuances of Common Stock - Sales: During November 2020, the Company sold 800,000 0.05 40,000 During February 2021, the Company sold an aggregate of 12,340,910 0.05 0.06 665,000 On February 22, 2021, the Company sold 1,818,181 0.055 100,000 0.086 56,364 During April 2021, the Company sold an aggregate of 13,677,821 0.03 0.25 535,000 During May 2021, the Company sold an aggregate of 2,087,822 0.13 0.15 286,250 During the period June 2021 through July 2021, the Company sold an aggregate of 11,541,500 0.05 0.13 631,020 During August 2021, the Company sold an aggregate of 3,000,000 0.05 150,000 During October 2021, the Company sold an aggregate of 7,500,000 0.04 300,000 In November 2021, the Company sold an aggregate of 8,000,000 0.05 400,000 In January 2022, the Company sold an aggregate of 666,667 20,000 In February 2022, the Company sold an aggregate of 8,333,333 0.03 250,000 During August 2022, in connection with the Closing, the Company sold an aggregate of 200,000,000 0.02 4,000,000 During August 2022 and September 2022, the Company sold an aggregate of 65,500,000 0.04 2,620,000 Issuances of Common Stock – Stock Based Compensation: In connection with the VP Agreements, each of the Sales Executives were granted 1,000,000 0.035 35,000 750,000 9,000,000 450,000 6,300,000 18,000,000 149,100 323,400 Effective March 29, 2021, the Company and Assure Immune L.L.C (“Consultant”) executed an amendment of the Consultant’s Agreement, whereby the Company issued to the Consultants 20,000,000 0.0614 1,228,000 614,000 358,167 During November 2020, the Company entered into an additional consulting agreement with a third party to provide consulting services in connection with the development of international research and development, sales and distribution and financing opportunities for a period of six months. As consideration for agreeing to provide the consulting services to the Company, the Company issued the consultant 2,000,000 0.151 302,000 2,000,000 185,400 0.093 92,700 92,700 During November 2020, in consideration for agreeing to provide medical consulting and advisory services to the Company, the Board approved the issuance to one individual an aggregate of 250,000 0.145 36,225 During December 2020, the Board approved the bonus of 47,675,000 45,000,000 2,000,000 550,000 125,000 0.12 5,721,000 During April 2021, the Board approved the bonus of 500,000 0.055 27,450 During December 2020, January 2021 and February 2021, the Company issued to various employees and consultants 25,000 240,000 50,000 0.035 0.17 19,855 During February 2021, the Company entered into a consulting agreement with a third party to provide consulting services for a one-year period. As consideration for agreeing to provide consulting services to the Company, the Company agreed to issue the consultant 500,000 250,000 75,000 1,500,000 0.095 47,500 11,875 35,625 During April 2021, the Company entered into a consulting agreement with a third party to provide investor relation services. The term of the agreement is month to month and may be terminated with or without cause. As consideration for agreeing to provide the consulting services to the Company, the Company has agreed to pay the consultants a minimum of $ 15,000 500,000 0.057 28,500 During March 2021, April 2021 and May 2021, the Company granted a total of 750,000 0.049 0.40 85,075 On June 4, 2021, the Company and an employee agreed to amendment of the employee’s employment agreement. Under the terms of the amendment, the employee agreed to extend the term of the agreement through December 31, 2022 and the Company agreed to grant the employee 1,000,000 0.136 136,000 100,211 35,789 During June 2021, the Company granted a total of 1,100,000 0.14 0.148 154,740 On June 10, 2021, the Company agreed to issue 60,000 10,000 0.167 On December 27, 2021, the Company and an employee agreed to an amendment of the employee’s employment agreement. Under the terms of the amendment, the employee agreed to extend the term of the agreement through December 31, 2024 and the Company agreed to increase the employee’s annual salary from $ 180,000 210,000 1,000,000 .029 29,000 22,958 On March 17, 2022, the Company entered into a consulting agreement with a third party to assist the Company with certain services associated with the implementation of the PPX TM 7,000,000 0.018 126,000 126,000 On June 9, 2022, the Company entered into a consulting agreement with a company affiliated with Mr. Sinnreich in connection with past and future consulting and advisory services to be provided to the Company. In connection with the consulting agreement, for the months of June 2022 and July 2022, the Company issued the consultant 1,700,000 2,000,000 0.019 0.0135 59,300 On July 21, 2022, in connection with the Term Sheet, Mr. Sinnreich was issued 10,000,000 0.0343 343,000 On July 21, 2022, in connection with the Term Sheet, during the first year of the Initial Term, Mr. Sinnreich will be compensated by the issuance of 24,000,000 shares of Organicell’s common stock upon execution of the Term Sheet, which shall vest pro-rata in equal monthly installments of 2,000,000 shares each. The shares issued were valued at $0.0343 per share, the closing price of the common stock of the Company on the effective date of the Term Sheet, totaling $823,200. On November 22, 2022, Mr. Sinnreich resigned from the Company. The Company will amortize the costs associated with the issuance through the date of Mr. Sinnreich’s termination. For the year ended October 31, 2022, a total of 6,706,849 shares had vested and the Company recorded $ 228,353 On August 18, 2022, the Company entered into a consulting agreement with a third party to provide strategic marketing and digital marketing services for a minimum period of six months. As consideration for agreeing to provide consulting services to the Company, the Company will pay the consultant $15,000 per month and issued the consultant 2,500,000 shares of unregistered common stock valued at $0.0241 per share, the closing price of the common stock of the Company on the effective date of the agreement. All of the shares granted vested immediately on the date of issuance. The Company will record $60,250 of stock-based compensation expense based on the grant date fair value of these shares during the term of the consulting agreement. The consulting agreement may be renewed for additional six-month periods under the same terms unless either party provides 30 days written notice to terminate. The Company recorded $ 25,104 On December 1, 2022, the Company granted 150,000 0.03 4,500 On December 29, 2022, the Company agreed to issue 5,000,000 100,000 0.02 Equity Line Of Credit Commitment: During November 2021, the Company entered into an term sheet agreement with Tysadco Partners LLC, a Delaware limited company (“Tysadco”) whereby Tysadco agreed to provide the Company with a $ 10,000,000 7,000,000 0.05 3,000,000 0.067 201,000 On September 1, 2022, the Company entered into a Purchase Agreement (the “Purchase Agreement”) with Tysadco and a Registration Rights Agreement (the “Registration Rights Agreement”) with Tysadco. Pursuant to the Purchase Agreement, Tysadco committed to purchase, subject to certain restrictions and conditions, up to $10,000,000 worth of the Company’s common stock (the “Commitment”), over a period of 24 months from the effectiveness of the registration statement registering the resale of shares purchased by Tysadco pursuant to the Purchase Agreement (the “Registration Statement”). Pursuant to the terms of the Registration Rights Agreement, the Company was obligated to use its commercially reasonable efforts to file a registration statement with the Securities and Exchange Commission within thirty (30) days after the date of such agreement, to register the resale by Tysadco of the shares of common stock issuable under the Purchase Agreement. On September 2, 2022, the Company filed the required registration statement and on October 24, 2022, the Registration Statement was declared effective. The Purchase Agreement provides that at any time after the effective date of the Registration Statement, from time to time on any business day selected by the Company (the “Purchase Date”), the Company shall have the right, but not the obligation, to direct Tysadco to buy the lesser of $1,000,000 in common stock per sale or 500% of the daily average share value traded for the 10 days prior to the closing request date, at a purchase price of 80% of the of the two lowest individual daily VWAPs during the ten (10) trading days preceding the draw down or put notice (“Valuation Period”), with a minimum request of $25,000 (“Request”). The payment for the shares covered by each request notice will occur on the business day immediately following the Valuation Period. In addition, Tysadco will not be obligated to purchase shares if Tysadco’s total number of shares beneficially held at that time would exceed 9.99% of the number of shares of the Company’s common stock as determined in accordance with Rule 13d-1(j) of the Securities Exchange Act of 1934, as amended. In addition, the Company is not permitted to draw on the Purchase Agreement unless the Registration Statement covering the resale of the shares is effective. The Purchase Agreement also contains customary representations and warranties of each of the parties. The assertions embodied in those representations and warranties were made for purposes of the Purchase Agreement and are subject to qualifications and limitations agreed to by the parties in connection with negotiating the terms of the Purchase Agreement. The Purchase Agreement further provides that the Company and Tysadco are each entitled to customary indemnification from the other for, among other things, any losses or liabilities they may suffer as a result of any breach by the other party of any provisions of the Purchase Agreement or Registration Rights Agreement. The Company has the unconditional right, at any time, for any reason and without any payment or liability, to terminate the Purchase Agreement. Pursuant to the Purchase Agreement, on December 2, 2022, the Company submitted a put request to Tysadco to purchase 4,456,326 registered shares at a purchase price of $0.02244, for a total of $100,000 (“Put Request”). On December 5, 2022, Tysadco funded the Put Request and the Company issued 4,456,326 shares to Tysadco. The proceeds from the share sale are being used for working capital and general corporate purposes. Shares Issued – Promissory Note: As described in Note 10, in connection with the issuance of the Promissory Note on January 11, 2022, the Company issued the Purchaser’s 3,076,923 123,000 Shares Issued – Amendment of consulting agreement: On August 19, 2022 the Company and a consultant (“Consultant”) agreed to an amendment to the consulting agreement whereby the Consultant was issued 5,000,000 20,000 The shares issued were valued at $0.0235 per share, the closing price of the common stock of the Company on the effective date of the settlement, totaling $117,500. The Company recorded a gain of $72,500 for the year ended October 31, 2022 in connection with the settlement, representing the difference in the fair value of the shares issued and the amount of obligations settled. Shares Issued – Settlement of Litigation: As described in Note 14, during April 2022 the Company settled a lawsuit whereby the Company paid LAE $ 45,000 2,000,000 43,800 Shares Repurchased – Settlement of Litigation: As described in Note 14, during January 2023, the Company settled a lawsuit by repurchasing 24,800,001 500,000 500,000 Issuances of Common Stock – Exchange of balances due on accounts payable for stock: During February 2021, the consulting arrangement was amended whereby the CMO’s accrued and unpaid consulting fees of $ 82,250 500,000 27,000 the CMO terminated his consulting arrangement with the Company and agreed to receive ten-year warrants to purchase 3,150,000 Shares at an exercise price of $0.02 per Share, exercisable on a “cashless basis as full satisfactory for all unpaid consulting fee obligations totaling $139,500. During May 2021, the Company and two employees agreed to exchange $ 30,973 176,989 0.175 Management and Consultants Performance Stock Plan On April 25, 2020, the Company approved the adoption of the Management and Consultants Performance Stock Plan (“MCPP”) providing for the grant to current senior executive members of management and third-party consultants shares of common stock of the Company (“Shares”) based on the achievement of certain defined operational performance milestones (“Milestones”). On February 10, 2021, the Board amended the MCPP, providing for the grant of common stock of the Company of 5 million shares for each Phase II clinical trial completed, 5 million shares for each Phase III clinical trial approved and initiated (deemed to be upon the time the first patient is enrolled) and 10.0 million shares for each Phase III clinical trial fully enrolled. In addition, the CMO’s portion of a designated grant for an achievement of any applicable Milestone subsequent to September 23, 2020 was reduced to 30% until the time that the CMO becomes a full-time employee of the Company. Pursuant to the MCPP, a total of 342,500,000 shares have been issued and as described above, additional shares are authorized to be issued under the MCPP subject to the achievement of the defined contingent performance based milestones described above and provided the milestones are achieved while the individual is employed and/or serving as a member of the Board: Schedule of management and consultants performance stock plan MCPP Shares Name Issued Albert Mitrani 80,000,000 Ian Bothwell 80,000,000 Dr. Maria Mitrani 80,000,000 Dr. George Shapiro 69,500,000 Dr. Allen Meglin - Michael Carbonara - Consultants 33,000,000 Total 342,500,000 In connection with the MCPP Shares that have been awarded to date, all such shares were issued in connection with the MCPP Shares approved on April 25, 2020 and accordingly were valued $0.027 per share, the closing price of the common stock of the Company on the date that those respective MCPP Shares were approved. During the years ended October 31, 2022 and 2021, a total 0 49,500,000 0 1,336,500 Upon completion of the Share Exchange on October 29, 2021, the MCPP (but not Awards of unexchanged shares of our common stock) was terminated. In connection with the Closing, the Company and each of the grantees of awards authorized but not yet issued under the MCPP (“Awards”) agreed to waive and terminate their respective Awards. 2021 Plan and Share Exchange Agreement In September 2021, the Company adopted the 2021 Equity Incentive Plan (“2021 Plan”). The 2021 Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units, and Performance Shares (an “Award”) to any person who is an employee or director of, or consultant to the Company. The maximum aggregate number of shares that may be issued pursuant to all Awards is 250,000,000 The 2021 Plan is administered by (a) the board of the directors of the Company; or (b) a committee designated by the board, which Committee shall be constituted in such a manner as to satisfy the applicable laws and to permit such grants and related transactions under the Plan to be exempt from Section 16(b) of the Exchange Act in accordance with Rule 16b-3. Once appointed, such committee shall continue to serve in its designated capacity until otherwise directed by the board. The board of directors may at any time amend, suspend, or terminate the Plan; provided, however, that no such amendment shall be made without the approval of the Company’s shareholders to the extent such approval is required by applicable laws. On October 29, 2021, the Company entered into an Exchange Agreement (the “Exchange Agreement”) with shareholders (including executive officers) who were issued shares under (i) various consulting and employment agreements during 2021 (the “Service Providers”), and (ii) those shareholders who were issued shares of common stock pursuant to the MCPP (the “MCPP Holders”). The Service Providers who executed the Exchange Agreement were issued a total of 30,300,000 shares under their respective consulting or employment agreements (the “Service Provider Shares”), and the MCPP Holders who executed the Exchange Agreement received a total of 49,500,000 shares under the MCPP, for an aggregate of 79,800,000 shares of common stock. As of the effective date of the Exchange Agreement, the Service Providers and MCPP Holders who executed the Exchange Agreement agreed to exchange their respective Service Provider Shares or the shares issued under the MCPP for newly issued shares pursuant to the 2021 Plan (on a 1:1 basis, resulting in the issuance of 79,800,000 shares of common stock under the 2021 Plan (the “Exchange Shares”). Upon completion of the Share Exchange, the 2020 Plan and the MCPP (but not Awards of unexchanged shares of our common stock) were terminated. The shares received in connection with the Exchange Agreement were treated as a modification to the original awards granted. The Company determined that there was not any incremental value resulting from the exchange and as a result there was no additional compensation costs recorded. As of October 31, 2022, a total of 83,400,000 Unvested Equity Instruments: A summary of unvested equity instruments outstanding for the years ended October 31, 2022 and 2021 are presented below: Schedule of non vested share activity Number of Weighted- Outstanding at October 31, 2021 83,844,445 $ 0.062 Non-Vested Shares Granted 25,900,000 $ 0.034 Vested 9,901,294 $ 0.040 Expired/Forfeited - $ - Outstanding at October 31, 2022 99,843,151 $ 0.057 Number of Weighted- Outstanding at October 31, 2020 1,111,111 $ 0.029 Non-Vested Shares Granted 83,400,000 $ 0.062 Vested 666,666 $ 0.029 Expired/Forfeited - $ - Outstanding at October 31, 2021 83,844,445 $ 0.062 As of October 31, 2022, the total compensation cost related to nonvested awards not yet recognized and the weighted-average period over which such costs are expected to be recognized was $ 855,030 7 As of October 31, 2021, the total compensation cost related to nonvested awards not yet recognized and the weighted-average period over which such costs are expected to be recognized was $ 1,093,022 14.3

WARRANTS

WARRANTS	12 Months Ended
	Oct. 31, 2022
Warrants
WARRANTS	NOTE 13 – WARRANTS A summary of warrant activity for the years ended October 31, 2022 and 2021 are presented below: Schedule of warrant activity Number of Weighted-average Remaining Aggregate Outstanding at October 31, 2021 9,500,000 $ 0.03 6.90 $ 289,500 Granted 420,300,000 $ 0.02 10.0 $ - Exercised - $ - - $ - Expired/Forfeited - $ - - $ - Outstanding at October 31, 2022 429,800,000 $ 0.02 9.63 $ 2,440,110 Exercisable at October 31, 2022 388,048,326 $ 0.02 9.62 $ 2,403,058 Number of Weighted-average Remaining Aggregate Outstanding at October 31, 2020 9,500,000 $ 0.03 7.90 $ 1,268,000 Granted - $ - - $ - Exercised - $ - - $ - Expired/Forfeited - $ - - $ - Outstanding and exercisable at October 31, 2021 9,500,000 $ 0.03 6.90 $ 289,500 On July 21, 2022, the Company issued Mr. Sinnreich a cashless warrant to purchase an aggregate of 40,000,000 0.034 2.91 10 144 0 1,332,000 1,332,000 At Closing, the Company also entered into 36-month consulting agreements with each of Skycrest and Greyt (each, a “Consulting Agreement,” and collectively, the “Consulting Agreements”), pursuant to which (a) Skycrest and Greyt will provide certain advisory services to the Company as more fully set forth therein; and (b) Skycrest and Greyt are being compensated for their services by the Company issuing to each of them at closing ten (10) year-warrants to purchase 150,000,000 0.02 2.91 10 144 0 2,940,000 2,940,000 408,333 At Closing, Ian Bothwell waived all unpaid and accrued compensation except for four unpaid base salary payments outstanding as of July 31, 2022, in exchange for ten-year warrants to purchase 30,000,000 0.02 2.91 10 144 0 588,000 455,478 At Closing, Dr. George Shapiro terminated his consulting arrangement with the Company and waived all unpaid consulting fee obligations in exchange for ten-year warrants to purchase 3,150,000 0.02 2.91 10 144 0 61,740 77,760 During August 2022, the Company entered into five separate consulting and employment agreements providing for the issuance of ten-year warrants to purchase an aggregate of 41,150,000 0.024 0.03 2.60 3.05 10 143 0 1,122,075 133,363 During September 2022, each of the five non-executive directors (other than the Chairman) were granted the right to be party to a Director’s Service Agreement. Pursuant to that agreement, non-employee directors will be compensated for their services by the annual issuance of warrants to acquire up to 1,000,000 0.044 3.69 10 143 0 43,200 23,079 Effective August 1, 2022, the Company entered into a one-year consulting agreement with a third party to provide strategic advice, assistance with implementation of new business strategies and overall advice concerning the Company’s business goals and objectives. The consultant shall receive compensation in the form of a warrant to acquire up to 1,000,000 0.033 2.60 10 143 0 32,700 8,175 All stock compensation expense is classified under general and administrative expenses in the consolidated statements of operations

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Oct. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 14 – COMMITMENTS AND CONTINGENCIES Executive Employment Agreements The Company is party to executive employment agreements with each of Ian T. Bothwell (our Interim Chief Executive Officer and Chief Financial Officer), Dr. Maria Ines Mitrani (our Chief Science Officer) and Albert Mitrani, our Executive Vice President of Sales), originally executed in April 2018 and subsequently amended (the “ Executive Employment Agreements 300,000 Pursuant to the terms of the SPA, the Executive Employment Agreements were further amended on August 19, 2022 and February 9, 2023 as follows: 1. Each of Albert Mitrani, Dr. Maria Ines Mitrani and Ian Bothwell amended their respective employment agreements providing for (a) setting their respective base salaries at $ 300,000 In addition, each of Albert Mitrani, Dr. Maria Ines Mitrani and Ian Bothwell agreed to a reduction in each executive’s annual salary to $ 150,000 2. Albert Mitrani and Dr. Maria Ines Mitrani each waived all accrued but unpaid compensation outstanding as of July 31, 2022. The Company, Albert Mitrani and Dr. Maria Ines Mitrani also agreed to terminate the leases with Mariluna LLC for use of Albert Mitrani’s and Mari Mitrani’s Miami, FL and Aspen, Colorado homes, retroactive to July 13, 2022. The Company wrote off the related ROU asset and lease liability as of the Closing Date. The balance of unpaid and accrued compensation that was forgiven by Albert Mitrani and Dr. Maria Ines Mitrani totaling $ 430,200 563,455 3. Ian Bothwell waived all unpaid and accrued compensation outstanding as of July 31, 2022, in exchange for ten-year warrants to purchase 30,000,000 0.02 455,478 4. Each of Albert Mitrani, Dr. Maria Ines Mitrani, Ian Bothwell and all other recipients agreed to terminate all awards granted but not yet issued under the Company’s Management and Consultant Performance Plan. 5. Each of Albert Mitrani, Dr. Maria Ines Mitrani and Ian Bothwell agreed to modify severance compensation provisions to be paid upon termination to only occur upon a termination without cause in an amount equal to one month’s base salary for each year of service. In connection with the February 9, 2023 amendment to the Executive Employment Agreements, Mr. Bothwell and Mr. Mitrani also agreed to repay approximately $ 44,600 84,300 Bonuses Effective December 21, 2020, the Company granted a bonus of $ 50,000 15,000,000 Term Sheet – Acting CEO On July 21, 2022 (“Effective Date”), Matthew Sinnreich was appointed by the Board of Directors to the position of Chief Operating Officer and Acting Chief Executive Officer. On the Effective Date, Organicell and Mr. Sinnreich entered into a term sheet (the “Term Sheet”) setting forth in principle the terms of Mr. Sinnreich’s employment agreement with and compensation by the Company. Except with respect to the signing bonus described below, the Term Sheet is subject to the negotiation and execution of a definitive employment agreement embodying the provisions of the Term Sheet, as well as customary terms and conditions for an executive employment agreement (the “Employment Agreement”). The parties agreed to use their respective commercial best efforts to negotiate and execute the Employment Agreement. The Term Sheet provides that as an inducement for Mr. Sinnreich to join the Company, within five (5) days of the Effective Date, he will be issued 10,000,000 40,000,000 0.034 343,000 1,332,000 The Employment Agreement will provide for an initial two-year term commencing on the Effective Date (the “Initial Term”), which will automatically renew for successive one-year terms (each a “Renewal Term,” and together with the Initial Term, the “Term”), unless terminated by either party upon not less than ninety (90) days’ prior written notice given before the expiration of the Initial Term or a Renewal Term, or earlier terminated as provided for therein. During the first year of the Initial Term, Mr. Sinnreich will be compensated by the issuance of 24,000,000 25,000 The Employment Agreement will provide that Mr. Sinnreich will be entitled to receive a bonus payment of $150,000, if and when during the Term, the Company generates $10,000,000 in funding from an equity line of credit arrangement that may be implemented by the Company in the future. In addition, Mr. Sinnreich will be entitled to receive an award of 15,000,000 shares of common stock if any of the following milestones are achieved during the Term and the twelve-month period thereafter (provided the Employment Agreement and Mr. Sinnreich’s employment thereunder is terminated by the Company without cause). 1. The Company first obtains market capitalization of $1.0 billion for a three-month consecutive period. 2. The Company first obtains market capitalization of $2.0 billion for a three-month consecutive period. 3. The Company first obtains market capitalization of $5.0 billion for a three-month consecutive period. 4. The Company first obtains market capitalization of $10.0 billion for a three-month consecutive period The offer and sale of the above referenced securities were and will be issued in private transactions exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), in reliance on exemptions afforded by Section 4(a)(2) of the Securities Act and the rules and regulations promulgated thereunder. As the Employment Agreement does not provide for cash compensation and in light of Mr. Sinnreich’s efforts in implementing the Company’s recent corporate restructuring and advancing its clinical trials, on September 7, 2022, the board of directors of the Company awarded Mr. Sinnreich a one-time payment of $200,000 and agreed to reimburse him for up to $100,000 in out-of-pocket expenses incurred by him in connection with services rendered to the Company, subject to submission of documentation for such expenses in accordance with the Company’s expense reimbursement policies. On September 13, 2022, Mr. Sinnreich assumed the position of President and Acting Chief Executive Officer. He subsequently resigned from the Company on November 22, 2022. The Company is currently reviewing its rights to rescind previously issued shares and payments to Mr. Sinnreich in light of the resignation. VP Agreements - Sales Executives On January 6, 2020, the Company entered into employment agreements with two individuals (“Sales Executives”), each to serve as a Vice President – Global Sales and Marketing. The terms of each Sales Executive employment agreement are identical (“VP Agreements”). The initial term of the VP agreements are for three years and provide for automatic annual renewals thereafter, unless either party provides 90-day written notice prior to expiration of the then current term. The VP Agreements may also be terminated by the Company beginning June 30, 2020 in the event the Sales Executive fails to meet certain defined minimum revenue growth milestones. The Sales Executives will receive compensation in the form of monthly salary of $18,000 and a quarterly override during the calendar year 2020 based on revenues earned by the Company during each quarterly period that exceed $600,000 (“Override Threshold”) beginning for the quarter ended June 30, 2020. The VP Agreements also require the Sales Executives and the Company to mutually agree on the Override Threshold for calendar years 2021 and 2022 to be eligible for the Override Threshold for those years, which has yet to be agreed to. Upon execution of the VP Agreements, each of the Sales Executives were granted 1,000,000 shares of unregistered common stock of the Company valued at $0.035 per share, the closing price of the common stock of the Company on the grant date. The VP Agreements also provide each Sales Executives the right to receive a minimum of 750,000 shares of common stock at the end of each quarterly anniversary of the VP Agreements throughout the Initial Term (maximum 9,000,000 shares) (“Performance Shares”). As of December 31, 2021, the Sales executives had been issued all of the Performance Shares. The VP Agreements were terminated on June 30, 2022 (see Legal Matters below). Consultant Agreements Assure Immune LLC Effective March 29, 2021, the Company and Assure Immune L.L.C (“Consultant”) entered into an amendment (“Amendment”) to the consulting agreement between the parties dated March 30, 2020 (“Agreement”). Under the terms of the Amendment, the initial term of the Agreement was extended for an additional 2 years (until March 30, 2023) and the terms for eligibility of the Consultants to receive future grants of stock above those stock issuances granted as of the date of the Amendment based on achievement of certain future milestones previously provided for in the Agreement were eliminated. In addition, the Amendment provided additional terms in connection with termination of the Agreement. Under the terms of the Amendment, the Consultant received an additional 20,000,000 shares of common stock that vest 50% upon execution of the Amendment and 50% on the sooner of (1) December 31, 2021 or (2) upon the approval of both of the Company’s IND’s to be submitted for Osteoarthritis and COVID 19 “Long Hauler”. On August 19, 2022 the Company and Consultant agreed to an amendment to the consulting agreement whereby the Consultant was issued 5,000,000 shares of common stock of the Company and received a $20,000 cash payment in exchange for satisfaction of approximately $200,000 in outstanding consulting fees due to the Consultant up through August 31, 2022. The parties also agreed to the reduction of future fees payable to the Consultant from $40,000 per month to $15,000 per month for the period September 2022 through March 2023. LAE International Consulting, LLC During October 2020, the Company entered into a consulting agreement with LAE International Consulting, LLC (“LAE”) to provide consulting services in connection with the development of international research and development, sales and distribution and investment opportunities. As consideration for agreeing to provide the consulting services to the Company, the Company has agreed to pay LAE a minimum of $12,500 per month for the first three months of the agreement and to issue up to 5,000,000 shares of restricted common stock (valued at $0.175 per share, the closing price of the common stock of the Company on the grant date), based on successful performance of defined milestones. Preparation of IRB, Pre-IND, IND Protocols for Clinical Applications and Clinical Trial Initiation and Monitoring: In connection with the Company’s ongoing research and development efforts and the Company’s efforts to meet compliance with current and anticipated United States Food and Drug Administration (“FDA”) regulations expected to be enforced beginning in May 2021 pertaining to marketing traditional biologics and human cells, tissues and cellular and tissue based products that fall under Section 351 of the Public Health Services Act (“HCT/Ps”), the Company has applied for and received Investigation New Drug (“IND”) approval from the FDA to commence clinical trials in connection with the use of the Company’s products and related treatment protocols for specific indications. The ability to successfully complete the above efforts will be dependent on the actual outcomes in connection with the use of the Company’s products and related treatment protocols for each clinical trial, the Company’s ability to timely enroll patients and fund the required payments and complete the applicable clinical trials, which is subject to available working capital generated from operations, financing arrangements with the third-party vendors involved in the studies and/or from additional debt and/or equity financings as well as the ultimate approval from the FDA. CRO Agreement 1 and CRO Agreement 2 During November 2020, the Company entered into an agreement with a third-party contract research organization (“CRO”) to provide ongoing clinical research related services in connection with a planned future clinical trial (“CRO Agreement 1”). In connection with the CRO Agreement 1, the Company was obligated to make payments of approximately $778,000 plus pass through costs and other third-party direct costs during the term of clinical trial expected to run until September 2021. In connection with the CRO Agreement 1, the Company was obligated to pay in accordance with defined completed milestones, beginning with approximately $195,524 upon work order execution. During January 2021, the Company entered into an additional agreement with the CRO to provide ongoing clinical research related services in connection with a planned future clinical trial (“CRO Agreement 2”). In connection with the CRO Agreement 2, the Company was obligated to payments of approximately $477,000 plus pass through costs and other third-party direct costs during the term of clinical trial expected to run until August 2021. In connection with the CRO Agreement 2, the Company was obligated to pay in accordance with defined completed milestones, beginning with approximately $147,000 upon work order execution. During February 2021, the Company provided notice to the CRO that it was terminating the engagement of the CRO in connection with the two above-described projects as a result of the significant increases in projected trial costs over the originally contracted amounts. On July 29, 2021, the parties reached a settlement agreement and general release in connection with termination of both of the agreements and all remaining past due amounts of $265,000 whereby the Company paid the CRO $100,000 and the Company was fully released from paying the remaining unpaid invoiced amounts of $145,000. For the year ended October 31, 2021, the Company has recorded approximately $390,000, net of expenses in connection with services performed by the CRO up through the date the projects were terminated. New CRO Agreements During August 2021, October 2021, and December 2021, the Company entered into agreements with a new CRO to provide ongoing clinical research and related services in connection with two of the Company’s approved clinical research trials (“New CRO Agreements”). On August 23, 2022 the New CRO Agreements were amended. In connection with the New CRO Agreements, the Company is obligated to make aggregate payments to the CRO of approximately $1,433,000 plus estimated aggregate pass-through costs and other third-party direct costs of approximately $495,000 as well as site and patient related costs. The Company is obligated to make the CRO payments based on the actual costs incurred over the term of the clinical trial beginning on the commencement of the work by the CRO in connection with the applicable clinical trial and the payments for the pass-through costs and other third-party direct costs as well as site and patient related costs are paid in accordance with completion of agreed upon milestones. As of October 31, 2022, the Company has been billed a total of approximately $680,000 in connection with the New CRO Agreements, including $18,400 of escrow related payments, of which approximately $ 244,900 Contingent Convertible Obligations Into Equity Securities Obligations Due Under Executive Employment Agreements Beginning July 1, 2020, at the sole option of the Executive, any portion of unpaid Original Base Salary for periods after January 1, 2020, including unpaid bonus salary, may be converted by Executive into common stock at a conversion rate equal to the average trading price during the month in which the accrued salary pertains. For any unpaid Original Base Salary that existed prior to January 1, 2020, including unpaid bonus salary, the amounts may be converted at a conversion price using the closing trading price of the stock on the last trading day in December 2019. As of October 31, 2021, there was approximately $721,000 of unpaid Original Base Salary and Incremental Salary related to the period prior to December 31, 2019 and approximately $760,000 of unpaid Original Base Salary and Incremental Salary related to the period January 1, 2020 through October 31, 2021, that could be converted in the future into approximately 35,685,000 shares of common stock (weighted average conversion price of $0.042 per share) . As of July 31, 2022, there was approximately $721,000 of unpaid Original Base Salary and Incremental Salary related to the period prior to December 31, 2019 and approximately $1,388,000 of unpaid Original Base Salary and Incremental Salary related to the period January 1, 2020 through July 31, 2022 . Leases Ethan NY On September 3, 2015, Ethan NY entered into a five-year lease agreement (“Ethan Lease”) for a store located in New York City, New York. The Ethan Lease commenced on October 1, 2015. Under the terms of the Ethan Lease, minimum monthly lease payments of $ 9,500 586,242 All of Ethan NY’s obligations under the Ethan Lease are recourse only to the assets at Ethan NY, except for certain obligations under the Ethan Lease that were guaranteed by a former employee. Under the terms of the Ethan Lease, the obligations of Ethan NY for future rents are to be mitigated based on the amount of any future rents that are received for the rental of the leased premises to other tenants during the initial term. During August 2016, Ethan NY received confirmation that the leased premises had been leased to another tenant. Ethan NY is not aware of any claim pending or threatened in connection with the Ethan Lease. At October 31, 2021, Ethan NY recorded in liabilities of discontinued operations the amount of rent obligations through June 30, 2016 and a reserve for estimated losses in connection with termination of the Ethan Lease of $101,905. In New York State, the statute of limitations for filing a breach of contract claim is 6 years. As a result, during the year ended October 31, 2022, the Company recorded a gain from the write-off of liabilities attributable to discontinued operations that were no longer enforceable due to the statute of limitations. Legal Matters SEC Matter On June 17, 2021, Organicell received a subpoena dated June 14, 2021, from the Atlanta Regional Office of the SEC requiring the production of certain documents and communications in connection with the treatment and results of various COVID-19 patients, as discussed in the Company’s Current Reports on Form 8-K filed with the SEC during the period from May 27, 2020 through May 11, 2021. The Company is fully cooperating with the SEC’s investigation and believes that it will be able to provide all of the information requested by the SEC. The Company can make no assurances as to the time or resources that will need to be devoted to this investigation or its final outcome, or the impact, if any, of this investigation or any proceedings on the Company’s current business, financial condition, results of operations, cash flows, or the Company’s future operations. LAE International Consulting On August 17, 2021, the Company was served with a summons and complaint by LAE International Consulting, LLC (“LAE”), in the case styled LAE International Consulting, LLC v. Organicell Regenerative Medicine, Inc. et al., Case No. 2021-018461-CA-01 (In the Circuit Court of the 11th Judicial Circuit in and for Miami Dade County, Florida) 45,000 2,000,000 Daniel Pepock and Tracy Yourke The Company terminated the employment agreements with the Sales Executives Daniel Pepock (“Pepock”) and Tracy Yourke (“Yourke”) effective June 30, 2022. On June 6, 2022, Pepock filed a Complaint against Organicell Regenerative Medicine, Inc. (“Organicell”) in the Court of Common Pleas of Westmoreland County, Pennsylvania. Organicell removed the case to the United States District Court for the Western District of Pennsylvania, and on July 15, 2022 Mr. Pepock filed an Amended Complaint asserting two counts. Count I alleges a claim for “Breach of Employment Agreement, including Violation of the Pennsylvania Wage Payment and Collection Law.” Mr. Pepock alleges that Organicell (i) failed to pay him certain wages in timely manner; (ii) failed to pay him commissions allegedly due; (iii) failed to pay him a severance benefit allegedly due; and (iv) improperly paid him as a 1099 “independent contractor” rather than a W-2 employee for the time period of January 1, 2020 through July 31, 2021. Mr. Pepock sought damages of $235,000 in compensation, plus compensation for alleged increased tax rates and decreased Social Security contributions, liquidated damages, costs of litigation including reasonable attorney fees and witness fees, interest on the judgment, plus any other relief the Court deems proper. Count II alleges a claim for “Fair Labor Standards Act Retaliatory Discharge”. Mr. Pepock alleged that he was unlawfully terminated in retaliation for filing a complaint about unpaid wages and sought damages in an unidentified amount of lost wage compensation, back pay, front pay, liquidated damages, compensation for pain and suffering and other non-economic damages, punitive damages, costs of litigation including reasonable attorney fees and witness fees, interest on the judgment, plus any other relief the Court deems proper. On June 27, 2022, Ms. Yourke filed a complaint against Organicell in the State of Michigan, 6 th Counts I and II alleged claims for “Breach of Employment Agreement and Violation of Michigan Sales Representative Commission Act”. Ms. Yourke alleged that Organicell (i) failed to pay her certain wages in timely manner; (ii) failed to pay her commissions allegedly due; (iii) failed to pay her a severance benefit allegedly due; and (iv) improperly treated her as a 1099 “independent contractor” rather than a W-2 employee for the time period of January 1, 2020 through July 31, 2021, April 16-30, 2022, and May 1, 2022 through June 30, 2022. Ms. Yourke sought an unidentified amount of damages in the form of compensation, commissions, treble damages, plus compensation for an alleged increased tax rates and increased Social Security contributions, costs of litigation, including actual attorney fees and witness fees, interest on the judgment, plus any other legal and equitable relief that the Court deems proper. Count III alleged a claim for “Fair Labor Standards Act Retaliatory Discharge”. Ms. Yourke alleged that she was unlawfully terminated in retaliation for filing a complaint about unpaid wages and sought damages in an unidentified amount of lost wage compensation, back pay, front pay, liquidated damages, compensation for pain and suffering and other non-economic damages, punitive damages, costs of litigation including reasonable attorney fees and witness fees, interest on the judgment, plus any other relief the Court deems proper. As of July 31, 2022, all past due wages to Pepock and Yourke were paid. Mr. Pepock’s action against Organicell was designated for placement into the United States District Court’s Alternative Dispute Resolution program and the Parties agreed to mediate. On August 22, 2022, Mr. Pepock, Ms. Yourke and Organicell agreed to a material settlement term sheet (“Settlement”) which provided for the resolution and full settlement and release of all claims among the parties and for the Company to buy back all of the shares of common stock of the Company issued to and owned by Mr. Pepock and Ms. Yourke at the time of the Settlement (represented by Mr. Pepock and Ms. Yourke to be in excess of 24,800,000 shares) in exchange for a payment by the Company of $500,000 (“Purchase Price”). In addition, the Company agreed to release Mr. Pepock and Ms. Yourke from their non-compete restrictions upon transfer of the shares to the Company. The Settlement relates to disputed claims and nothing therein shall be construed as an admission of liability or wrongdoing by the Company or any other party. Effective October 13, 2022, the parties executed a Confidential Settlement Agreement and Mutual General Release memorializing the terms of the Settlement. On January 31, 2023, 24,800,001 shares were transferred to the Company and the Company paid the Purchase Price. The shares received by the Company were immediately cancelled and returned to the Company’s treasury of authorized and unissued shares. As a result of the above, the matter has been fully settled and Mr. Pepock and Ms. Yourke were released from their non-compete restrictions. At October 31, 2022, the Company has recorded the obligation to repurchase the shares in connection with settlement of the litigation in the amount of $500,000 in the consolidated balance sheet. In addition to the foregoing, from time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in any such matter may harm our business.

LIABILITIES ATTRIBUTABLE TO DIS

LIABILITIES ATTRIBUTABLE TO DISCONTINUED OPERATIONS	12 Months Ended
	Oct. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
LIABILITIES ATTRIBUTABLE TO DISCONTINUED OPERATIONS	NOTE 15 – LIABILITIES ATTRIBUTABLE TO DISCONTINUED OPERATIONS During September 2015, the Company formed Ethan NY for the purpose of selling clothing and accessories through a retail store. During June 2016, the Ethan NY operations were closed. The following summarizes the carrying amounts of the assets and liabilities of Ethan NY at October 31, 2022 and 2021: Schedule of assets and liabilities October 31, 2022 2021 Assets $ - $ - Liabilities: Accounts Payable $ - $ 94,835 Accrued Expenses - 31,016 Total liabilities $ - $ 125,851 In New York State, the statute of limitations for filing a breach of contract claim is 6 years. As a result, during the year ended October 31, 2022, the Company recorded a gain from the write-off of liabilities attributable to discontinued operations that were no longer enforceable due to the statute of limitations.

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Oct. 31, 2022
Segment Reporting [Abstract]
SEGMENT INFORMATION	NOTE 16 – SEGMENT INFORMATION For the years ended October 31, 2022 and 2021, the Company operated only one 1

401(K) PLAN

401(K) PLAN	12 Months Ended
	Oct. 31, 2022
K Plan
401(K) PLAN	NOTE 17 – 401(K) PLAN The Company sponsors a pooled defined contribution retirement plan (“401(k) Plan”) covering all eligible employees effective January 25, 2023. The 401(k) Plan allows eligible employees to contribute, subject to Internal Revenue Service limitations on total annual contributions, up to 92% of their compensation as defined in the 401(k) Plan, to various investment funds. Under the 401(k) Plan, the Company may, but is not obligated to, make any contributions to the 401(K) Plan for any eligible employees. The Company has no

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Oct. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 18 – SUBSEQUENT EVENTS Several subsequent events are disclosed in Notes 8, 10, 12, 13, 14 and 17. There were no other subsequent events for disclosure purposes.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Oct. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Reclassifications	Reclassifications Certain comparative figures have been reclassified to conform to the current year financial statement presentation. These reclassifications had no effect on the reported results of operations. An adjustment has been made to the Consolidated Statements of Cash Flows for the year ended October 31, 2021 to reclassify certain payments for the purchase of fixed assets.
Concentrations of Risk	Concentrations of Risk Credit Risk The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $ 250,000 3,731,290 Major Customer During the fiscal year ended October 31, 2022, the Company sold a total of approximately $ 2,124,000 32.7 1,413,700 21.8 702,100 10.8 During the fiscal year ended October 31, 2021, the Company sold a total of approximately $ 2,140,000 37.6 709,000 12.5 881,600 15.7 The Company’s sales agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products. Major Supplier During the fiscal year ended October 31, 2022, the Company purchased the tissue raw material used in manufacturing of its products from two suppliers, of which each accounted for approximately $ 145,000 130,000 53.0 47.0 During the fiscal year ended October 31, 2021, the Company purchased the tissue raw material used in manufacturing of its products from two suppliers, of which each accounted for approximately $ 148,600 131,600 53.0 47.0 The Company’s supply agreements are non-exclusive and the Company does not believe it has any exposure based on the availability of raw materials and/or products from other suppliers.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at net realizable value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to pay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. For the year ended October 31, 2022 and 2021, the Company recorded bad debt expense of $ 27,500 0
Inventory	Inventory Inventory is stated at the lower of cost or net realizable value using the average cost method. The Company provides a reserve for potential excess, dated or obsolete inventories based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life. At October 31, 2022, the Company wrote off $ 37,455
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of property and equipment range from 3 15
Leasehold Improvements	Leasehold Improvements Leasehold improvements in excess of $1,000 that are made in connection with leases having a term of more than 12 months are capitalized by the Company and amortized over the shorter of the useful life of the asset or the remaining lease periods and renewals that are deemed to be reasonably certain at the date the leasehold improvements are purchased. Costs associated with leasehold improvements that do not exceed $1,000 are expensed as incurred.
Revenue Recognition	Revenue Recognition The Company follows the guidance of FASB Accounting Standards Update (“ASU”) Topic 606 “Revenue from Contracts with Customers” which requires the Company to recognize revenue in amounts that reflect the prorata completion of the performance obligations of the Company required under the contracts. The Company recognizes revenue only when it transfers control of a promised good or service to a customer in an amount that reflects the consideration it expects to receive in exchange for the good or service. Our performance obligations are satisfied and control is transferred at a point-in-time, which is typically when the transfer and title to the product sold has taken place and there is evidence of our customer’s satisfactory acceptance of the product shipment or delivery except in those instances when the customer has made prior arrangements with the Company to store the product purchased by the customer at the Company’s facilities that is to be delivered at a later date to be designated by the customer.
Net Income (Loss) Per Common Share	Net Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of fully vested common shares outstanding during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of fully vested shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity instruments. At October 31, 2022, the Company had 388,048,326 9,500,000 35,684,900
Stock-Based Compensation	Stock-Based Compensation All stock-based payments are recognized in the financial statements based on their fair values.
Research and Development Costs	Research and Development Costs Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Our research and development expenses were $ 791,326 1,120,067
Income Taxes	Income Taxes The Company files a consolidated tax return that includes all of its subsidiaries. Provisions for income taxes are based on taxes payable or refundable for the current year taxable income for federal and state income tax reporting purposes and deferred income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of the operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with FASB Topic 740 – Income Taxes. This pronouncement prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. The interpretation also provides guidance on recognition, derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. For the years ended October 31, 2022 and 2021 the Company incurred operating losses, and therefore, there was not any income tax expense amount recorded during those periods. There is a full valuation allowance established for the tax benefit associated with the net losses for the years ended October 31, 2022 and 2021.
Valuation of Derivatives	Valuation of Derivatives The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date.
Sequencing	Sequencing The Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares. The Company currently has 2,500,000,000 1,463,957,717
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made. The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments. The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Level one Level two Level three The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company did not have any convertible instruments outstanding at October 31, 2022 and October 31, 2021 that contain derivatives.
Operating Lease Obligations	Operating Lease Obligations Under the provisions of Accounting Standards Update (ASU) No. 2016-02 (Topic 842) (“ASC 842”), the Company recognizes a right of use (“ROU”) asset and corresponding lease liability for all operating leases upon commencement of the lease. The Company applies the modified retrospective approach which includes a number of optional practical expedients on leases that commenced before the effective date of ASC 842, including continuing to account for leases that commenced before the effective date in accordance with previous guidance, unless the lease is modified and the inclusion of amounts pertaining to the maintenance portion of the leased assets. The Company’s policy is to treat operating leases that have a term of one year or less at lease commencement date and do not include a purchase option that is reasonably certain of exercise, consistent with the lease recognition approach as previously outlined under ASC 840. In addition, month to month leases which do not involve additional financial commitments on the part of the Company are also treated consistent with the lease recognition approach as previously outlined under ASC 840. The Company has established a capitalization threshold of $ 15,000
Subsequent Events	Subsequent Events The Company has evaluated subsequent events that occurred after October 31, 2022 through the financial statement issuance date for subsequent event disclosure or recording.

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Oct. 31, 2022
Inventory Disclosure [Abstract]
Schedule of inventories	Schedule of inventories October 31, October 31, Raw materials and supplies $ 85,096 $ 92,601 Finished goods 163,414 142,226 Total inventories $ 248,510 $ 234,827

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Oct. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Schedule of property and equipment October 31, October 31, Computer equipment $ 26,881 $ 10,684 Finance lease equipment 544,378 544,378 Manufacturing equipment 625,979 258,791 Leasehold improvements 925,932 - 2,123,170 813,853 Less: accumulated depreciation and amortization (439,654 ) (107,146 ) 1,683,516 706,707 Construction in progress - 406,709 Total property and equipment, net $ 1,683,516 $ 1,113,416

LEASE OBLIGATIONS (Tables)

LEASE OBLIGATIONS (Tables)	12 Months Ended
	Oct. 31, 2022
Lease Obligations
Schedule of minimum lease payment to finance lease	Schedule of minimum lease payment to finance lease Minimum Year Ended October 31, Rent 2023 $ 139,868 2024 83,783 2025 65,731 2026 65,731 2027 32,864 Thereafter - Total undiscounted finance lease payments 387,977 Less: imputed interest (23,889 ) Present value of finance lease liabilities $ 364,088
Schedule of minimum lease payment to finance lease	Schedule of minimum lease payment to finance lease Minimum Year Ended October 31, Rent 2023 $ 237,606 2024 28,857 Thereafter - Total undiscounted operating lease payments 266,463 Less: imputed interest (3,590 ) Present value of operating lease liabilities $ 262,873

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Oct. 31, 2022
Payables and Accruals [Abstract]
Schedule of account payable and accrued expenses	Schedule of account payable and accrued expenses October 31, October 31, Accrued payroll related liabilities $ 666,780 $ 504,979 Lab equipment and supplies payables 477,255 117,606 Clinical trial payables 312,711 26,325 Legal fees payables 328,121 214,725 Other professional fees payables 90,993 259,442 Accrued IRS penalty 83,684 83,684 Accrued commissions payable 39,675 119,439 Construction payables 5,474 238,347 Other payables and accrued expenses 373,838 308,475 Accounts Payable and Accrued Expenses $ 2,378,531 $ 1,873,022

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Oct. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of provision for income tax	Schedule of provision for income tax Year Ended Year Ended 2022 2021 Current: Federal $ - $ - State - - Current Income Tax Expense (Benefit) $ - $ - Deferred: Federal $ 4,405,121 $ (2,651,809 ) State 1,079,723 (563,409 ) Deferred Income Tax Expense (Benefit) 5,484,844 (3,215,218 ) Change in Valuation Allowance (5,484,844 ) 3,215,218 Income tax provision $ - $ -
Schedule of effective income tax rate	Schedule of effective income tax rate October 31, October 31, Tax at federal statutory rate $ (1,868,277 ) $ (2,678,878 ) State taxes, net of federal benefit (386,555 ) (554,273 ) Permanent differences 400,100 27,070 Stock-based compensation 6,609,802 - Executive Forgiveness of employment obligations In connection with Restructuring 480,109 - Other 249,665 (9,137 ) Total income tax expense (benefit) 5,484,844 (3,215,218 ) Change in valuation allowance (5,484,844 ) 3,215,218 Income tax provision $ - $ -
Schedule of deferred tax assets and liabilities	Schedule of deferred tax assets and liabilities October 31, October 31, Deferred Tax Assets: Stock based compensation $ 798,239 $ 7,281,332 Accrued compensation - 480,109 Net operating loss carryforward-Federal 3,002,402 1,512,039 Net operating loss carryforward-State 396,530 282,780 Other 1,477 177 Total deferred tax assets: 4,198,648 9,556,437 Deferred Tax Liabilities: Property and equipment 302,447 175,392 Total deferred tax liabilities: 302,447 175,392 Valuation Allowance (3,896,201 ) (9,381,045 ) Net deferred tax assets $ - $ -

CAPITAL STOCK (Tables)

CAPITAL STOCK (Tables)	12 Months Ended
	Oct. 31, 2022
Equity [Abstract]
Schedule of management and consultants performance stock plan	Schedule of management and consultants performance stock plan MCPP Shares Name Issued Albert Mitrani 80,000,000 Ian Bothwell 80,000,000 Dr. Maria Mitrani 80,000,000 Dr. George Shapiro 69,500,000 Dr. Allen Meglin - Michael Carbonara - Consultants 33,000,000 Total 342,500,000
Schedule of non vested share activity	Schedule of non vested share activity Number of Weighted- Outstanding at October 31, 2021 83,844,445 $ 0.062 Non-Vested Shares Granted 25,900,000 $ 0.034 Vested 9,901,294 $ 0.040 Expired/Forfeited - $ - Outstanding at October 31, 2022 99,843,151 $ 0.057 Number of Weighted- Outstanding at October 31, 2020 1,111,111 $ 0.029 Non-Vested Shares Granted 83,400,000 $ 0.062 Vested 666,666 $ 0.029 Expired/Forfeited - $ - Outstanding at October 31, 2021 83,844,445 $ 0.062

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Oct. 31, 2022
Warrants
Schedule of warrant activity	Schedule of warrant activity Number of Weighted-average Remaining Aggregate Outstanding at October 31, 2021 9,500,000 $ 0.03 6.90 $ 289,500 Granted 420,300,000 $ 0.02 10.0 $ - Exercised - $ - - $ - Expired/Forfeited - $ - - $ - Outstanding at October 31, 2022 429,800,000 $ 0.02 9.63 $ 2,440,110 Exercisable at October 31, 2022 388,048,326 $ 0.02 9.62 $ 2,403,058 Number of Weighted-average Remaining Aggregate Outstanding at October 31, 2020 9,500,000 $ 0.03 7.90 $ 1,268,000 Granted - $ - - $ - Exercised - $ - - $ - Expired/Forfeited - $ - - $ - Outstanding and exercisable at October 31, 2021 9,500,000 $ 0.03 6.90 $ 289,500

LIABILITIES ATTRIBUTABLE TO D_2

LIABILITIES ATTRIBUTABLE TO DISCONTINUED OPERATIONS (Tables)	12 Months Ended
	Oct. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Schedule of assets and liabilities	Schedule of assets and liabilities October 31, 2022 2021 Assets $ - $ - Liabilities: Accounts Payable $ - $ 94,835 Accrued Expenses - 31,016 Total liabilities $ - $ 125,851

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Feb. 03, 2023	Jan. 04, 2021	Dec. 21, 2020
Product Information [Line Items]
FDIC limits per institutions	$ 250,000
Cash Balances	3,731,290
Revenues	6,491,008	$ 5,597,487
Cost of revenues	753,534	547,881
Bad debt expense	27,500	$ 0
Inventory Reserve	37,455
Incremental salary		35,684,900
Research and Development Expense	$ 791,326	$ 1,120,067
Common stock, shares authorized	2,500,000,000	2,500,000,000		2,500,000,000	1,500,000,000
Common stock, shares issued	1,479,126,390	1,132,361,005
Common stock, shares outstanding	1,479,126,390	1,132,361,005
Operating and finance lease obligation	$ 15,000
Subsequent Event [Member]
Product Information [Line Items]
Common stock, shares authorized			2,500,000,000
Common stock, shares issued			1,463,957,717
Common stock, shares outstanding			1,463,957,717
Common Shares Issuable Upon Exercise Of Warrants [Member]
Product Information [Line Items]
Antidilutive securities excluded from computation of earnings per share	388,048,326	9,500,000
Minimum [Member]
Product Information [Line Items]
Property, plant and equipment, estimated useful lives	3 years
Maximum [Member]
Product Information [Line Items]
Property, plant and equipment, estimated useful lives	15 years
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Large Distributor And Distributors Customers [Member]
Product Information [Line Items]
Revenues	$ 2,124,000	$ 2,140,000
Concentration credit risk percentage	32.70%	37.60%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customers Of Another Distributor [Member]
Product Information [Line Items]
Revenues	$ 1,413,700	$ 709,000
Concentration credit risk percentage	21.80%	12.50%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Management Services Organization [Member]
Product Information [Line Items]
Revenues	$ 702,100	$ 881,600
Concentration credit risk percentage	10.80%	15.70%
Tissue Raw Material [Member] | Customer Concentration Risk [Member] | First Supplier [Member]
Product Information [Line Items]
Concentration credit risk percentage	53%	53%
Cost of revenues	$ 145,000	$ 148,600
Tissue Raw Material [Member] | Customer Concentration Risk [Member] | Second Supplier [Member]
Product Information [Line Items]
Concentration credit risk percentage	47%	47%
Cost of revenues	$ 130,000	$ 131,600

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net losses	$ 8,896,557	$ 12,756,560
Accumulated deficit	50,521,306	$ 41,624,749
Working capital deficit	$ 303,085

RESTRUCTURING (Details Narrativ

RESTRUCTURING (Details Narrative) - USD ($)		1 Months Ended
	Jul. 13, 2022	Aug. 19, 2022	Jul. 21, 2022	Jul. 16, 2022	Mar. 17, 2022	Dec. 27, 2021	Nov. 30, 2021	Jun. 10, 2021	Jun. 04, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share price						$ 0.029	$ 0.067	$ 0.167	$ 0.136
Letter of intent description				Skycrest/Greyt Group and Beyond 100 each advanced Organicell $400,000 and $300,000, respectively (a total of $700,000) as good faith deposits against the $2,000,000 (a total of $4,000,000) purchase price for the Shares.
Consulting Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock purchased		5,000,000
Share price					$ 0.018
Skycrest Holdings [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment	$ 2,000,000
Number of common stock purchased	100,000,000
Share price	$ 0.02
Beyond 100 F Z E [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment				$ 2,000,000
Number of common stock purchased				100,000,000
Share price				$ 0.02
Skycrest [Member] | Consulting Agreement [Member] | Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of warrants purchased			150,000,000
Exercise Price			$ 0.02

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Oct. 31, 2022	Oct. 31, 2021
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 85,096	$ 92,601
Finished goods	163,414	142,226
Total inventories	$ 248,510	$ 234,827

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Oct. 31, 2022	Oct. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,123,170	$ 813,853
Less: accumulated depreciation	(439,654)	(107,146)
Total property and equipment, net before leasehold improvements	1,683,516	706,707
Total property and equipment, net	1,683,516	1,113,416
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	26,881	10,684
Finance lease equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	544,378	544,378
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	625,979	258,791
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	925,932
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Construction in progress		$ 406,709

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 82,036	$ 52,702
Amortization expense	$ 250,472

LEASE OBLIGATIONS (Details)

LEASE OBLIGATIONS (Details)	Oct. 31, 2022 USD ($)
Lease Obligations
2023	$ 139,868
2024	83,783
2025	65,731
2026	65,731
2027	32,864
Thereafter
Total undiscounted finance lease payments	387,977
Less: imputed interest	(23,889)
Present value of finance lease liabilities	$ 364,088

LEASE OBLIGATIONS (Details 1)

LEASE OBLIGATIONS (Details 1)	Oct. 31, 2022 USD ($)
Lease Obligations
2023	$ 237,606
2024	28,857
Thereafter
Total undiscounted operating lease payments	266,463
Less: imputed interest	(3,590)
Present value of operating lease liabilities	$ 262,873

LEASE OBLIGATIONS (Details Narr

LEASE OBLIGATIONS (Details Narrative) - USD ($)		1 Months Ended			12 Months Ended
	Oct. 10, 2022	Aug. 30, 2022	Mar. 31, 2021	Mar. 31, 2019	Oct. 31, 2022	Oct. 31, 2021	Jun. 30, 2022	May 31, 2021	Oct. 03, 2020	Jul. 02, 2020	Feb. 28, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease obligation					$ 262,873
Security deposit					39,936	$ 47,682
Lease expense					29,670	38,037
Mari Luna [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Minimum monthly lease payments									$ 6,500	$ 3,500
Operating lease obligation										$ 117,659
Borrowing rate										4.50%
Security deposit					5,000				$ 11,000
Basalt Lab Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease obligation			$ 235,313
Borrowing rate			4.50%
Lease expense			$ 6,800
Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment to acquire				$ 239,595		304,873
Monthly payments				$ 4,513		$ 5,478
Operating leased equipment, per unit				1		1
Annual interest rate				4.50%		3%
Estimated useful lives of leased equipment				15 years		15 years
Security deposit		$ 10,000
Annual rent		$ 160,000
Miami Lab Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Minimum monthly lease payments							$ 9,500	$ 8,000
Security deposit											$ 6,332
Annual base license fee	$ 20,230
Second Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Security deposit			13,600		11,000
Basalt Lab Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment to acquire			$ 925,932
Lease expense					$ 76,351	$ 47,967

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)

1 Months Ended

12 Months Ended

Jun. 30, 2022

Oct. 31, 2021

Oct. 29, 2021

Feb. 26, 2021

Oct. 31, 2020

Jul. 31, 2020

Feb. 26, 2020

Oct. 31, 2022

Oct. 31, 2021

Dec. 21, 2021

Mar. 31, 2021

Oct. 03, 2020

Related Party Transaction [Line Items]

Aggregate shares

50,000,000

Security deposit

$ 47,682

$ 39,936

$ 47,682

Rent expenses

31,500

42,000

Payment for certain expenses

$ 36,352

31,192

Unpaid and accrued compensation description

Ian Bothwell waived all unpaid and accrued compensation in the amount of $1,043,478, in exchange for ten-year warrants to purchase 30,000,000 Shares at an exercise price of $0.02 per share, exercisable on a “cashless basis” and a cash payment of $50,000 at Closing. At Closing, Dr. George Shapiro terminated his consulting arrangement with the Company and waived all unpaid consulting fee obligations in the amount of $139,500 in exchange for ten-year warrants to purchase 3,150,000 Shares at an exercise price of $0.02 per share, exercisable on a “cashless basis.”

Chief Medical Officer [Member]

Related Party Transaction [Line Items]

Compensation

$ 82,250

Unpaid consulting fees

$ 82,250

Shares of newly issued common stock

500,000

Mr. Mitrani [Member]

Related Party Transaction [Line Items]

Bonus

$ 50,000

Dr. Mari Mitrani [Member]

Related Party Transaction [Line Items]

Bonus

15,000,000

Consulting fees

362,455

Mr. Bothwell [Member]

Related Party Transaction [Line Items]

Payment for certain expenses

$ 0

6,253

Bonus

$ 1,000,000

Albert Mitrani [Member]

Related Party Transaction [Line Items]

Consulting fees

275,924

Ian Bothwell [Member]

Related Party Transaction [Line Items]

Consulting fees

843,478

Michael Carbonara [Member]

Related Party Transaction [Line Items]

Related parties

101,715

20,820

101,715

Michael Carbonara 1 [Member]

Related Party Transaction [Line Items]

Related parties

$ 32,655

13,820

32,655

Albert Mitrani [Member]

Related Party Transaction [Line Items]

Capital contribution

$ 250,000

Second Lease Agreement [Member]

Related Party Transaction [Line Items]

Security deposit

11,000

$ 13,600

Monthly rent expense

$ 6,500

Rent expenses

58,500

78,000

Executive Employment Agreements [Member] | Albert Mitrani [Member]

Related Party Transaction [Line Items]

Unpaid and accrued compensation forgiven

430,200

Executive Employment Agreements [Member] | Dr Maria Ines Mitrani [Member]

Related Party Transaction [Line Items]

Unpaid and accrued compensation forgiven

563,455

Mari Luna [Member]

Related Party Transaction [Line Items]

Security deposit

5,000

$ 11,000

Monthly rent expense

$ 3,500

Management Services Organization [Member]

Related Party Transaction [Line Items]

Proceed from sale of products

$ 702,100

$ 881,600

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)	Oct. 31, 2022	Oct. 31, 2021
Payables and Accruals [Abstract]
Accrued payroll related liabilities	$ 666,780	$ 504,979
Lab equipment and supplies payables	477,255	117,606
Clinical trial payables	312,711	26,325
Legal fees payables	328,121	214,725
Other professional fees payables	90,993	259,442
Accrued IRS penalty	83,684	83,684
Accrued commissions payable	39,675	119,439
Construction payables	5,474	238,347
Other payables and accrued expenses	373,838	308,475
Accounts Payable and Accrued Expenses	$ 2,378,531	$ 1,873,022

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)				1 Months Ended						9 Months Ended	12 Months Ended
	Jun. 10, 2021	Jun. 04, 2021	Feb. 05, 2019	Aug. 20, 2022	Jan. 24, 2022	Nov. 30, 2021	Feb. 28, 2021	Jan. 31, 2021	Dec. 31, 2020	Jul. 31, 2022	Oct. 31, 2022	Oct. 31, 2021	Jul. 11, 2022	Jan. 11, 2022	Dec. 27, 2021	Jun. 20, 2018
Debt Instrument [Line Items]
Interest rate													10%
Proceeds from note payble											$ 518,500
Number of shares issued	60,000	1,000,000				3,000,000	50,000	240,000	25,000
Share price	$ 0.167	$ 0.136				$ 0.067									$ 0.029
Repayment of promissory note											300,000
Common stock issued as commitment fee for Promissory Note											156,231
Commitment Fee Shortfall Obligation											143,769
Commitment fee discount											323,111
Commitment fee shortfall obligation											174,462
Proceeds from unsecured line of credit											$ 100,000
Interest rate											45.67%
J H Darbie [Member]
Debt Instrument [Line Items]
Legal fees											$ 12,500
Brokerage fees											$ 9,000
Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Principal amount														$ 600,000
Discount														$ 60,000
Number of shares reserved											36,923,080
Commitment fee											$ 123,000
Number of shares issued											3,076,923
Share price											$ 0.04
Unsecured Promissory Note [Member] | Third Party [Member]
Debt Instrument [Line Items]
Principal amount			$ 25,000
Maturity date			Mar. 08, 2019
Related parties											$ 0	4,392
Unsecured Promissory Note [Member]
Debt Instrument [Line Items]
Unpiad professional fees					$ 278,340
Promissory note					256,000
Cash payment					166,000
Periodic payment					7,500
Payments for notes receivable					$ 22,340
Additional Commitment [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Commitment fee											$ 33,231
Number of shares issued											1,538,462
Share price											$ 0.0216
Promissory Note [Member]
Debt Instrument [Line Items]
Discount											$ 60,000
Promissory note discount											260,000
Common stock issued as commitment fee for Promissory Note										$ 123,000	123,000
Commitment Fee Shortfall Obligation											77,000
Additional promissory note discount											100,000
Additional Fair value of Commitment Fee Share											33,231
Additional Commitment fee shortfall obligation											66,769
Commitment fee discount											323,111
Fair value of Commitment Fee Share											125,538
Commitmnet shortfall obligation												$ 30,692
Commitment fee shortfall obligation											174,462
Accredited Investors [Member]
Debt Instrument [Line Items]
Principal amount																$ 150,000
Interest rate																6%
Payment for debt settlement				$ 87,500
Gain on settlement of debt											$ 35,041

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Current:
Federal
State
Current Income Tax Expense (Benefit)
Deferred:
Federal	4,405,121	(2,651,809)
State	1,079,723	(563,409)
Deferred Income Tax Expense (Benefit)	5,484,844	(3,215,218)
Change in Valuation Allowance	(5,484,844)	3,215,218
Income tax provision

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Income Tax Disclosure [Abstract]
Tax at federal statutory rate	$ (1,868,277)	$ (2,678,878)
State taxes, net of federal benefit	(386,555)	(554,273)
Permanent differences	400,100	27,070
Stock-based compensation	6,609,802
Executive Forgiveness of employment obligations In connection with Restructuring	480,109
Other	249,665	(9,137)
Total income tax expense (benefit)	5,484,844	(3,215,218)
Change in valuation allowance	(5,484,844)	3,215,218
Income tax provision

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($)	Oct. 31, 2022	Oct. 31, 2021
Deferred Tax Assets:
Stock based compensation	$ 798,239	$ 7,281,332
Accrued compensation		480,109
Net operating loss carryforward-Federal	3,002,402	1,512,039
Net operating loss carryforward-State	396,530	282,780
Other	1,477	177
Total deferred tax assets:	4,198,648	9,556,437
Deferred Tax Liabilities:
Property and equipment	302,447	175,392
Total deferred tax liabilities:	302,447	175,392
Valuation Allowance	(3,896,201)	(9,381,045)
Net deferred tax assets

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2011
Income Tax Disclosure [Abstract]
Statutory income tax rate	21%	21%
Federal operating loss carryforward	$ 14,297,151
State operating loss carryforward	9,126,151
State operating loss carryforward indefinitely	6,554,845
Penalties	90,000		$ 20,000
Accrued tax penalties	$ 83,684	$ 83,684

CAPITAL STOCK (Details)

CAPITAL STOCK (Details)	12 Months Ended
	Oct. 31, 2022 shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Mcpp shares awarded	342,500,000
Albert Mitrani [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Mcpp shares awarded	80,000,000
Ian Bothwell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Mcpp shares awarded	80,000,000
Maria I. Mitrani [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Mcpp shares awarded	80,000,000
George Shapiro [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Mcpp shares awarded	69,500,000
Allen Meglin [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Mcpp shares awarded
Michael Carbonara [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Mcpp shares awarded
Consultants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Mcpp shares awarded	33,000,000

CAPITAL STOCK (Details 1)

CAPITAL STOCK (Details 1) - $ / shares	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Equity [Abstract]
Number of Nonvested Shares, Outstanding at beginning	83,844,445	1,111,111
Weighted-Average Grant Date Value, Outstanding at beginning	$ 0.062	$ 0.029
Number of Non-Vested Shares, Granted	25,900,000	83,400,000
Weighted-Average Grant Date Value, Granted	$ 0.034	$ 0.062
Number of Non-Vested Shares, Vested	9,901,294	666,666
Weighted-Average Grant Date Value, Vested	$ 0.040	$ 0.029
Number of Non-Vested Shares, Expired/Forfeited
Weighted-Average Grant Date Value, Expired/Forfeited
Number of Nonvested Shares, Outstanding at ending	99,843,151	83,844,445
Weighted-Average Grant Date Value, Outstanding at ending	$ 0.057	$ 0.062

CAPITAL STOCK (Details Narrativ

CAPITAL STOCK (Details Narrative) - USD ($)						1 Months Ended																															2 Months Ended	3 Months Ended			9 Months Ended	11 Months Ended	12 Months Ended
	Dec. 01, 2022	Jan. 11, 2022	Jun. 10, 2021	Jun. 04, 2021	Jan. 04, 2021	Jan. 31, 2023	Dec. 29, 2022	Dec. 27, 2022	Aug. 31, 2022	Aug. 19, 2022	Jul. 21, 2022	Apr. 30, 2022	Mar. 17, 2022	Feb. 28, 2022	Jan. 31, 2022	Dec. 31, 2021	Dec. 27, 2021	Nov. 30, 2021	Oct. 31, 2021	Oct. 31, 2021	Aug. 31, 2021	Jun. 30, 2021	May 31, 2021	May 31, 2021	May 21, 2021	Apr. 30, 2021	Apr. 27, 2021	Mar. 31, 2021	Feb. 28, 2021	Feb. 22, 2021	Jan. 31, 2021	Dec. 31, 2020	Dec. 21, 2020	Nov. 30, 2020	Oct. 31, 2020	Jun. 30, 2020	Jul. 31, 2021	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Jul. 31, 2022	Sep. 30, 2021	Oct. 31, 2022	Oct. 31, 2021	Feb. 03, 2023	Aug. 01, 2022	Jul. 21, 2021
Class of Stock [Line Items]
Preferred stock, shares authorized																																							10,000,000				10,000,000
Preferred stock, par value																																							$ 0.001				$ 0.001
Common stock, shares authorized					2,500,000,000														2,500,000,000	2,500,000,000													1,500,000,000						2,500,000,000				2,500,000,000	2,500,000,000
Common stock shares converted																																											$ 7,270,000	$ 2,707,270
Stock based compensation																																											3,916,590	8,652,307
Share price			$ 0.167	$ 0.136													$ 0.029	$ 0.067
Stock issued for services, shares																	1,000,000
Stock-based compensation expense								$ 22,958																																			35,789	100,211
Stock issued			$ 10,000																																								0	49,500,000
Stock issued during period			60,000	1,000,000														3,000,000											50,000		240,000	25,000
Stock granted of period value				$ 136,000													$ 29,000																								$ 201,000
Annual salary																	180,000
Increasing annual salary																	$ 210,000
Cash provided for credit facility																		$ 10,000,000
Purchase of restricted common shares																		7,000,000
Share price																		$ 0.05					$ 0.175	$ 0.175
Common stock shares converted		3,076,923
Common stock issued as commitment fee for Promissory Note																																											156,231
Lawsuit settlement by cash												$ 45,000																															$ 45,000
Lawsuit settlement by issuance of restricted common stock												2,000,000																															2,000,000
Settlement of Litigation												$ 43,800
Repurchase value																																											500,000
Newly issued common stock																							176,989
Commission payables																							$ 30,973
Stock-based compensation expense																																											$ 0	1,336,500
Plan and share exchange agreement																			The Service Providers who executed the Exchange Agreement were issued a total of 30,300,000 shares under their respective consulting or employment agreements (the “Service Provider Shares”), and the MCPP Holders who executed the Exchange Agreement received a total of 49,500,000 shares under the MCPP, for an aggregate of 79,800,000 shares of common stock. As of the effective date of the Exchange Agreement, the Service Providers and MCPP Holders who executed the Exchange Agreement agreed to exchange their respective Service Provider Shares or the shares issued under the MCPP for newly issued shares pursuant to the 2021 Plan (on a 1:1 basis, resulting in the issuance of 79,800,000 shares of common stock under the 2021 Plan (the “Exchange Shares”). Upon completion of the Share Exchange, the 2020 Plan and the MCPP (but not Awards of unexchanged shares of our common stock) were terminated.
Total compensation cost to non vested																			$ 1,093,022	$ 1,093,022																			$ 855,030				$ 855,030	$ 1,093,022
Weighted-average period contractual term																																											7 months	14 months 9 days
N 22021 Plan [Member]
Class of Stock [Line Items]
Maximum aggregate number of shares																			250,000,000
2021 Plan Member
Class of Stock [Line Items]
Shares issued																																							83,400,000				83,400,000
Promissory Note [Member]
Class of Stock [Line Items]
Common stock issued as commitment fee for Promissory Note																																									123,000		$ 123,000
Subsequent Event [Member]
Class of Stock [Line Items]
Common stock, shares authorized																																													2,500,000,000
Number of common stock repurchase						24,800,001
Repurchase value						500,000
Employee [Member]
Class of Stock [Line Items]
Share price	$ 0.03
Number of shares granted	150,000
Employee [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Stock based compensation																																						$ 4,500
Service Provider [Member]
Class of Stock [Line Items]
Share price							$ 0.02
Stock granted of period value							$ 100,000
Number of shares granted							5,000,000
Consulting Agreement [Member]
Class of Stock [Line Items]
Stock based compensation																																											126,000
Share price													$ 0.018
Stock granted of period value													$ 126,000
Number of unregistered common stock issued													7,000,000
Number of common stock issued										5,000,000
Proceeds from stock issued										$ 20,000
Consulting Agreement [Member] | Sinnreich [Member]
Class of Stock [Line Items]
Stock based compensation																																							$ 25,104	$ 343,000			$ 59,300
Share price																																			$ 0.0135	$ 0.019											$ 0.0343
Number of unregistered common stock issued																																			2,000,000	1,700,000
Number of restricted common stock vested											10,000,000
Consulting Agreement 1 [Member] | Sinnreich [Member]
Class of Stock [Line Items]
Stock based compensation																																								$ 228,353	$ 228,353
Five Accredited Investors [Member]
Class of Stock [Line Items]
Sale of stock, price per share																														$ 0.086
Minimum [Member]
Class of Stock [Line Items]
Share price																													$ 0.035
Maximum [Member]
Class of Stock [Line Items]
Share price																													$ 0.17
Accredited Investors [Member]
Class of Stock [Line Items]
Additional shares issued																																		800,000
Sale of stock, price per share																																		$ 0.05
Common stock shares converted																																		$ 40,000
Five Accredited Investors [Member]
Class of Stock [Line Items]
Additional shares issued																													12,340,910
Common stock shares converted																													$ 665,000
Five Accredited Investors [Member] | Minimum [Member]
Class of Stock [Line Items]
Sale of stock, price per share																													$ 0.05
Five Accredited Investors [Member] | Maximum [Member]
Class of Stock [Line Items]
Sale of stock, price per share																													0.06
Dr. Allen Meglin [Member]
Class of Stock [Line Items]
Additional shares issued																											500,000			1,818,181
Share price																											$ 0.055
Stock-based compensation expense																																										$ 27,450
Republic Asset Holdings LLC [Member]
Class of Stock [Line Items]
Sale of stock, price per share																														$ 0.055
Common stock shares converted																														$ 100,000
Stock based compensation																																												$ 56,364
Seven Accredited Investors [Member]
Class of Stock [Line Items]
Additional shares issued																										13,677,821
Common stock shares converted																										$ 535,000
Seven Accredited Investors [Member] | Minimum [Member]
Class of Stock [Line Items]
Sale of stock, price per share																										$ 0.03
Seven Accredited Investors [Member] | Maximum [Member]
Class of Stock [Line Items]
Sale of stock, price per share																										$ 0.25
Eight Accredited Investors [Member]
Class of Stock [Line Items]
Additional shares issued																								2,087,822
Common stock shares converted																								$ 286,250
Eight Accredited Investors [Member] | Minimum [Member]
Class of Stock [Line Items]
Sale of stock, price per share																							$ 0.13	$ 0.13
Eight Accredited Investors [Member] | Maximum [Member]
Class of Stock [Line Items]
Sale of stock, price per share																							$ 0.15	$ 0.15
Four Accredited Investors [Member]
Class of Stock [Line Items]
Additional shares issued									65,500,000											7,500,000																	11,541,500
Sale of stock, price per share																																							$ 0.04				$ 0.04			$ 0.04
Common stock shares converted									$ 2,620,000											$ 300,000																	$ 631,020
Four Accredited Investors [Member] | Minimum [Member]
Class of Stock [Line Items]
Sale of stock, price per share																																					$ 0.05
Four Accredited Investors [Member] | Maximum [Member]
Class of Stock [Line Items]
Sale of stock, price per share																																					$ 0.13
One Accredited Investors [Member]
Class of Stock [Line Items]
Additional shares issued														8,333,333	666,667			8,000,000			3,000,000
Sale of stock, price per share														$ 0.03	$ 20,000			$ 0.05			$ 0.05
Common stock shares converted														$ 250,000				$ 400,000			$ 150,000
Several Accredited Investors [Member]
Class of Stock [Line Items]
Additional shares issued														200,000,000
Sale of stock, price per share															$ 0.02
Common stock shares converted														$ 4,000,000
Sales Executives [Member]
Class of Stock [Line Items]
Stock based compensation																																											$ 35,000
Common stock granted																																											1,000,000
Share price																																							0.035				$ 0.035
Shares vested																																											18,000,000
Sales Executives [Member] | Minimum [Member]
Class of Stock [Line Items]
Common stock shares converted																																											$ 750,000
Sales Executives [Member] | Maximum [Member]
Class of Stock [Line Items]
Common stock shares converted																																											9,000,000
Sales Executive [Member]
Class of Stock [Line Items]
Stock based compensation																																											149,100	323,400
Consultants [Member] | Consultants Agreement [Member]
Class of Stock [Line Items]
Stock based compensation																																											614,000	$ 358,167
Common stock granted																																												20,000,000
Share price																			$ 0.0614	$ 0.0614																								$ 0.0614
Amortization of Debt Issuance Costs																																											$ 1,228,000
Consultant [Member]
Class of Stock [Line Items]
Share price																		$ 0.151							$ 0.057				$ 0.095										$ 0.093				$ 0.093
Stock issued for services, shares																		2,000,000							500,000				250,000														2,000,000
Stock-based compensation expense																																											$ 302,000
Stock issued																													$ 47,500														185,400
Stock issued during period																						1,100,000				750,000		750,000	500,000
Services paid																									$ 15,000
Consultant [Member] | Minimum [Member]
Class of Stock [Line Items]
Share price																						$ 0.14				$ 0.049		$ 0.049
Marketing services																													$ 75,000
Consultant [Member] | Maximum [Member]
Class of Stock [Line Items]
Share price																						$ 0.148
Marketing services																													1,500,000
Two Individuals [Member]
Class of Stock [Line Items]
Stock-based compensation expense																																											92,700	$ 92,700
One Individual [Member]
Class of Stock [Line Items]
Share price																		$ 0.145
Stock issued for services, shares																		250,000
Stock-based compensation expense																																											36,225
Dr. Mari Mitrani [Member]
Class of Stock [Line Items]
Share price																																$ 0.12
Stock-based compensation expense																																$ 5,721,000
Stock issued during period																47,675,000
Mr. Bothwell [Member]
Class of Stock [Line Items]
Stock issued during period																45,000,000
Consultant Five [Member]
Class of Stock [Line Items]
Stock-based compensation expense																																											19,855
Consultant 1 [Member]
Class of Stock [Line Items]
Stock-based compensation expense																																											11,875	$ 35,625
Consultant 2 [Member]
Class of Stock [Line Items]
Stock-based compensation expense																																											28,500
Consuktant [Member] | Maximum [Member]
Class of Stock [Line Items]
Share price																										$ 0.40		$ 0.40
Consultant Three [Member]
Class of Stock [Line Items]
Stock-based compensation expense																																											$ 85,075
Consultant Four [Member]
Class of Stock [Line Items]
Stock-based compensation expense																						$ 154,740
Board of Directors Chairman [Member]
Class of Stock [Line Items]
Voting right, percentage					voting equivalency of 53.55%																												voting equivalency of 53.55%
Non-executive Board Members [Member]
Class of Stock [Line Items]
Stock issued during period																2,000,000
Administrative Staff [Member]
Class of Stock [Line Items]
Stock issued during period																550,000
Medical Advisors [Member]
Class of Stock [Line Items]
Stock issued during period																125,000
Chief Medical Officer [Member]
Class of Stock [Line Items]
Unpaid consulting fees																													$ 82,250
Newly issued common stock																													500,000
Compensation receive																													$ 27,000
Warrant to purchase description																													the CMO terminated his consulting arrangement with the Company and agreed to receive ten-year warrants to purchase 3,150,000 Shares at an exercise price of $0.02 per Share, exercisable on a “cashless basis as full satisfactory for all unpaid consulting fee obligations totaling $139,500.
Series C Non Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized																																							100				100
Preferred stock, par value																																							$ 0.001				$ 0.001
Common Stock [Member] | Sales Executives [Member]
Class of Stock [Line Items]
Shares vested																																											450,000	6,300,000

WARRANTS (Details)

WARRANTS (Details) - Warrant [Member] - USD ($)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Number of Shares Outstanding beginning balance	9,500,000	9,500,000
Weighted-average Exercise Price Outstanding beginning balance	$ 0.03	$ 0.03
Remaining Contractual Term (years) Outstanding beginning balance	6 years 10 months 24 days	7 years 10 months 24 days
Aggregate Intrinsic Value Outstanding beginning balance	$ 289,500	$ 1,268,000
Number of Shares, Granted	420,300,000
Weighted-average Exercise Price, Granted	$ 0.02
Remaining Contractual Term (years) Granted	10 years
Aggregate Intrinsic Value, Granted
Number of Shares, Exercised
Weighted-average Exercise Price, Exercised
Aggregate Intrinsic Value, Exercised
Number of Shares, Expired/Forfeited
Weighted-average Exercise Price, Expired/Forfeited
Aggregate Intrinsic Value, Expired/Forfeited
Number of Shares Outstanding ending balance	429,800,000	9,500,000
Weighted-average Exercise Price Outstanding ending balance	$ 0.02	$ 0.03
Remaining Contractual Term (years) Outstanding ending balance	9 years 7 months 17 days	6 years 10 months 24 days
Aggregate Intrinsic Value Outstanding ending balance	$ 2,440,110	$ 289,500
Number of Shares Exercisable	388,048,326
Weighted-average Exercise Price Exercisable	$ 0.02
Remaining Contractual Term (years) Exercisable	9 years 7 months 13 days
Aggregate Intrinsic Value Exercisable	$ 2,403,058

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)		1 Months Ended			3 Months Ended		12 Months Ended
	Aug. 01, 2022	Sep. 30, 2022	Aug. 31, 2022	Jul. 21, 2022	Oct. 31, 2022	Jul. 31, 2022	Oct. 31, 2022	Oct. 31, 2022	Oct. 31, 2021
Share based compensation expense							$ 3,916,590		$ 8,652,307
Consulting Agreement [Member]
Share based compensation expense							126,000
Sinnreich [Member] | Consulting Agreement [Member]
Share based compensation expense					$ 25,104	$ 343,000	59,300
Warrant [Member] | Consulting Agreement [Member]
Share based compensation expense							408,333
Warrant [Member] | Five Separate Consulting And Employment Agreements [Member]
Number of warrants purchased			41,150,000
Term			10 years
Expected stock volatility			143%
Expected dividend rate			0%
Grant date fair value of warrants issued			$ 1,122,075
Share based compensation expense								$ 133,363
Warrant [Member] | Five Separate Consulting And Employment Agreements [Member] | Minimum [Member]
Exercise Price			$ 0.024
Risk free interest rate			2.60%
Warrant [Member] | Five Separate Consulting And Employment Agreements [Member] | Maximum [Member]
Exercise Price			$ 0.03
Risk free interest rate			3.05%
Warrant [Member] | Sinnreich [Member]
Number of warrants purchased				40,000,000
Exercise Price				$ 0.034
Risk free interest rate				2.91%
Term				10 years
Expected stock volatility				144%
Expected dividend rate				0%
Grant date fair value of warrants issued				$ 1,332,000
Share based compensation expense							$ 1,332,000
Warrant [Member] | Skycrest [Member] | Consulting Agreement [Member]
Number of warrants purchased				150,000,000
Exercise Price				$ 0.02
Risk free interest rate				2.91%
Term				10 years
Expected stock volatility				144%
Expected dividend rate				0%
Grant date fair value of warrants issued				$ 2,940,000
Warrant [Member] | Greyt [Member] | Consulting Agreement [Member]
Number of warrants purchased				150,000,000
Exercise Price				$ 0.02
Risk free interest rate				2.91%
Term				10 years
Expected stock volatility				144%
Expected dividend rate				0%
Grant date fair value of warrants issued				$ 2,940,000
Warrant [Member] | Ian Bothwell [Member]
Number of warrants purchased							30,000,000
Exercise Price							$ 0.02
Risk free interest rate							2.91%
Term							10 years
Expected stock volatility							144%
Expected dividend rate							0%
Grant date fair value of warrants issued							$ 588,000
Unpaid and accrued compensation forgiven							$ 455,478
Warrant [Member] | Dr George Shapiro [Member]
Number of warrants purchased							3,150,000
Exercise Price							$ 0.02
Risk free interest rate							2.91%
Term							10 years
Expected stock volatility							144%
Expected dividend rate							0%
Grant date fair value of warrants issued							$ 61,740
Unpaid and accrued compensation forgiven							77,760
Warrant [Member] | Five Non Executive Directors [Member] | Directors Service Agreement [Member]
Number of warrants purchased		1,000,000
Exercise Price		$ 0.044
Risk free interest rate		3.69%
Term		10 years
Expected stock volatility		143%
Expected dividend rate		0%
Grant date fair value of warrants issued		$ 43,200
Share based compensation expense							23,079
Warrant [Member] | Third Party [Member] | Consulting Agreement [Member]
Number of warrants purchased	1,000,000
Exercise Price	$ 0.033
Risk free interest rate	2.60%
Term	10 years
Expected stock volatility	143%
Expected dividend rate	0%
Grant date fair value of warrants issued	$ 32,700
Share based compensation expense							$ 8,175

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)

1 Months Ended

9 Months Ended

12 Months Ended

Feb. 09, 2023

Oct. 31, 2022

Aug. 19, 2022

Jul. 21, 2022

Jun. 30, 2022

Apr. 30, 2022

Mar. 29, 2021

Jul. 31, 2022

Oct. 31, 2022

Oct. 31, 2021

Dec. 15, 2022

Nov. 30, 2022

Dec. 27, 2021

Apr. 30, 2018

Sep. 03, 2015

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Annual salary

$ 180,000

Sales executives,description

The Sales Executives will receive compensation in the form of monthly salary of $18,000 and a quarterly override during the calendar year 2020 based on revenues earned by the Company during each quarterly period that exceed $600,000 (“Override Threshold”) beginning for the quarter ended June 30, 2020. The VP Agreements also require the Sales Executives and the Company to mutually agree on the Override Threshold for calendar years 2021 and 2022 to be eligible for the Override Threshold for those years, which has yet to be agreed to.

Contract research organization outstanding

$ 244,900

$ 244,900

Executive employment agreements description

there was approximately $721,000 of unpaid Original Base Salary and Incremental Salary related to the period prior to December 31, 2019 and approximately $1,388,000 of unpaid Original Base Salary and Incremental Salary related to the period January 1, 2020 through July 31, 2022. In connection with the Closing, the Company and each of the Executives agreed to forego their unpaid Original Base Salary and Incremental Salary (see “Changes in Management Compensation” above).

there was approximately $721,000 of unpaid Original Base Salary and Incremental Salary related to the period prior to December 31, 2019 and approximately $760,000 of unpaid Original Base Salary and Incremental Salary related to the period January 1, 2020 through October 31, 2021, that could be converted in the future into approximately 35,685,000 shares of common stock (weighted average conversion price of $0.042 per share)

Lawsuit settlement by cash

$ 45,000

$ 45,000

Lawsuit settlement by issuance of restricted common stock

2,000,000

2,000,000

Ian Bothwell [Member] | Warrant [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Unpaid and accrued compensation forgiven

$ 455,478

Number of warrants purchased

30,000,000

Exercise Price

$ 0.02

Sinnreich [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Base salary

$ 25,000

Number of restricted shares issued

10,000,000

Value of restricted shares issued

$ 343,000

Number of shares issued for compensation

24,000,000

Sinnreich [Member] | Warrant [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Number of warrants purchased

40,000,000

Exercise Price

$ 0.034

Value of warrants purchased

$ 1,332,000

Executive Employment Agreements [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Annual salary

$ 300,000

Executive Employment Agreements [Member] | Albert Mitrani [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Annual salary

$ 150,000

Base salary

$ 300,000

Unpaid and accrued compensation forgiven

$ 430,200

Bonus

$ 50,000

Issuance of common stock

15,000,000

Executive Employment Agreements [Member] | Dr Maria Ines Mitrani [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Annual salary

$ 150,000

Base salary

300,000

Unpaid and accrued compensation forgiven

$ 563,455

Bonus

$ 50,000

Issuance of common stock

15,000,000

Executive Employment Agreements [Member] | Ian Bothwell [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Annual salary

$ 150,000

Base salary

$ 300,000

Reimbursed expenses

$ 44,600

Bonus

$ 50,000

Issuance of common stock

15,000,000

Executive Employment Agreements [Member] | Mr. Mitrani [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Reimbursed expenses

$ 84,300

Consultant Agreements [Member] | Assure Immune [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Consultant agreements,description

Company and Consultant agreed to an amendment to the consulting agreement whereby the Consultant was issued 5,000,000 shares of common stock of the Company and received a $20,000 cash payment in exchange for satisfaction of approximately $200,000 in outstanding consulting fees due to the Consultant up through August 31, 2022. The parties also agreed to the reduction of future fees payable to the Consultant from $40,000 per month to $15,000 per month for the period September 2022 through March 2023.

Under the terms of the Amendment, the Consultant received an additional 20,000,000 shares of common stock that vest 50% upon execution of the Amendment and 50% on the sooner of (1) December 31, 2021 or (2) upon the approval of both of the Company’s IND’s to be submitted for Osteoarthritis and COVID 19 “Long Hauler”.

Consultant Agreements [Member] | L A E International Consulting [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Consultant agreements,description

Company has agreed to pay LAE a minimum of $12,500 per month for the first three months of the agreement and to issue up to 5,000,000 shares of restricted common stock (valued at $0.175 per share, the closing price of the common stock of the Company on the grant date), based on successful performance of defined milestones.

Ethan Lease Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Minimum monthly lease payments

$ 9,500

Total amount of minimum lease payments

$ 586,242

LIABILITIES ATTRIBUTABLE TO D_3

LIABILITIES ATTRIBUTABLE TO DISCONTINUED OPERATIONS (Details) - USD ($)	Oct. 31, 2022	Oct. 31, 2021
Total liabilities		$ 125,851
Ethan N Y [Member]
Assets
Accounts Payable		94,835
Accrued Expenses		31,016
Total liabilities		$ 125,851

SEGMENT INFORMATION (Details Na

SEGMENT INFORMATION (Details Narrative) - Integer	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Segment Reporting [Abstract]
Number of operating segments	1	1

401(K) PLAN (Details Narrative)

401(K) PLAN (Details Narrative)	12 Months Ended
	Oct. 31, 2022 USD ($)
K Plan
Contributions	$ 0